




加科思藥業集團有限公司

JACOBIO PHARMACEUTICALS GROUP CO., LTD.

(Incorporated in the Cayman Islands with limited liability)


Stock Code: 1167



2022
INTERIM REPORT

Contents

2	Corporate Information
4	Financial Highlights
5	Business Highlights
7	Management Discussion and Analysis
29	Supplementary Information
38	Definitions and Glossary
44	Report on Review of Interim Financial Information
45	Interim Condensed Consolidated Statement of Loss
46	Interim Condensed Consolidated Statement of Comprehensive Loss
47	Interim Condensed Consolidated Balance Sheet
49	Interim Condensed Consolidated Statement of Changes in Shareholders' Equity
50	Interim Condensed Consolidated Statement of Cash Flows
51	Notes to the Condensed Consolidated Interim Financial Information



Corporate Information

BOARD OF DIRECTORS

Executive Directors

Dr. Yinxiang WANG (王印祥) (*Chairman*)
Ms. Xiaojie WANG (王曉潔)
Ms. Yunyan HU (胡雲雁)
Dr. Shaojing HU (胡邵京)
(*resigned with effect from March 22, 2022*)

Non-executive Directors

Dr. Ting FENG (馮婷)
(*resigned with effect from March 22, 2022*)
Ms. Yanmin TANG (唐豔旻)
Dr. Dong LYU (呂東)
Dr. Te-li CHEN (陳德禮)

Independent Non-executive Directors

Dr. Ruilin SONG (宋瑞霖)
Dr. Ge WU (吳革)
Dr. Daqing CAI (蔡大慶)
Dr. Xiaoming WU (吳曉明)
(*resigned with effect from March 22, 2022*)

AUDIT COMMITTEE

Dr. Daqing CAI (蔡大慶) (*Chairman*)
Dr. Ge WU (吳革)
Dr. Te-li CHEN (陳德禮)

REMUNERATION COMMITTEE

Dr. Ruilin SONG (宋瑞霖) (*Chairman*)
Ms. Xiaojie WANG (王曉潔)
Ms. Yanmin TANG (唐豔旻)
Dr. Ge WU (吳革)
Dr. Daqing CAI (蔡大慶)

NOMINATION COMMITTEE

Dr. Yinxiang WANG (王印祥) (*Chairman*)
Dr. Dong LYU (呂東)
Dr. Ruilin SONG (宋瑞霖)
Dr. Daqing CAI (蔡大慶)
Dr. Xiaoming WU (吳曉明)
(*resigned with effect from March 22, 2022*)
Dr. Ge WU (吳革)
(*appointed with effect from March 22, 2022*)

JOINT COMPANY SECRETARIES

Ms. Qing XUE (薛青)
Mr. Lok Kwan YIM (嚴洛鈞) (*FCG, HKFCG*)
(*resigned with effect from August 24, 2022*)
Mr. Ming Fai CHUNG (鍾明輝) (*appointed with effect from August 24, 2022*)

AUTHORISED REPRESENTATIVES

Ms. Xiaojie WANG (王曉潔)
Mr. Lok Kwan YIM (嚴洛鈞) (*FCG, HKFCG*)
(*resigned with effect from August 24, 2022*)
Mr. Ming Fai CHUNG (鍾明輝) (*appointed with effect from August 24, 2022*)

AUDITOR

PricewaterhouseCoopers

Certified Public Accountants and Registered Public Interest Entity Auditor
22/F, Prince's Building
Central
Hong Kong

COMPLIANCE ADVISOR

Somerley Capital Limited

20th Floor, China Building
29 Queen's Road Central
Central, Hong Kong

REGISTERED OFFICE

Walkers Corporate Limited

190 Elgin Avenue
George Town
Grand Cayman KY1-9008
Cayman Islands

CORPORATE HEADQUARTERS

Building F2, No. 88, Kechuang 6th Street
Beijing Economic-Technological Development Area
Beijing
PRC

PRINCIPAL PLACE OF BUSINESS IN HONG KONG

40/F, Dah Sing Financial Centre
248 Queen's Road East
Wanchai
Hong Kong

Corporate Information

PRINCIPAL SHARE REGISTRAR

Walkers Corporate Limited

190 Elgin Avenue
George Town
Grand Cayman KY1-9008
Cayman Islands

WEBSITE

<http://www.jacobiopharma.com>

STOCK CODE

1167

HONG KONG BRANCH SHARE REGISTRAR

Computershare Hong Kong Investor Services Limited

Shops 1712-1716, 17th Floor
Hopewell Centre
183 Queen's Road East
Wan Chai
Hong Kong

LEGAL ADVISERS

As to Hong Kong and United States laws:

Cooley HK

35/F, Two Exchange Square
8 Connaught Place
Central
Hong Kong

PRINCIPAL BANKERS

In Hong Kong

Bank of China (Hong Kong) Limited

24/F, Bank of China Tower
1 Garden Road
Central
Hong Kong

In the United States

Silicon Valley Bank

3003 Tasman Drive
Santa Clara
CA 95054
USA

In the PRC

Agricultural Bank of China Beijing Branch

No. 88 Kechuang Street 6th
Beijing Economic-Technological Development Area
Beijing
PRC

Financial Highlights

REVENUE

We recorded RMB54.7 million for the six months ended June 30, 2022 which was attributable to R&D costs reimbursement generated from the license and collaboration agreement with AbbVie regarding the R&D, manufacture and commercialization of our SHP2 inhibitors.

RESEARCH AND DEVELOPMENT EXPENSES

Our research and development expenses increased by RMB54.9 million or 45.1% from RMB121.7 million for the six months ended June 30, 2021 to RMB176.6 million for the six months ended June 30, 2022, primarily due to the advancements of our clinical candidates, the expansion of pre-clinical research portfolio and the increased staff costs accompanied with the expansion of relevant R&D departments.

ADMINISTRATIVE EXPENSES

Our administrative expenses increased by RMB4.3 million or 23.2% from RMB18.5 million for the six months ended June 30, 2021 to RMB22.8 million for the six months ended June 30, 2022. This was primarily attributable to the increase in employee benefit expenses and other administrative expenses which was in line with our business expansion.

LOSS FOR THE PERIOD

As a result of the above factors, the loss for the period decreased from RMB136.6 million for the six months ended June 30, 2021 to RMB127.8 million for the six months ended June 30, 2022.

Business Highlights

During the Reporting Period, our Group continued advancing our drug pipeline and business operations, including the following milestones and achievements:

PROGRESS OF CORE PIPELINE PRODUCTS:

- **JAB-3312 (SHP2 inhibitor)**

We have completed the global Phase I dose escalation portion for the combination of JAB-3312 and a KRAS G12C inhibitor Sotorasib in July 2022.

In China, we have received the IND approval of Phase I/IIa clinical trial of JAB-3312 in combination with our KRAS G12C inhibitor JAB-21822 and the first patient was dosed in May 2022. Partial response (PR) was observed in the first NSCLC patient enrolled in the first dose level.

- **JAB-21822 (KRAS G12C inhibitor)**

The preliminary clinical data of the Phase I study of JAB-21822 in advanced solid tumors in China was reported at the 2022 annual meeting of American Society of Clinical Oncology (“**2022 ASCO Annual Meeting**”) in June 2022. We have also initiated the Phase II dose expansion in China and a total of 50 NSCLC patients at the RP2D have been treated as of July 31, 2022. With the favorable efficacy and safety profile, the pivotal trial in patients with NSCLC harboring KRAS G12C mutation is expected to start in the second half of 2022.

In the U.S. and Europe, the first patient with tumors harboring KRAS G12C mutation of the Phase I trial was dosed in September 2021 and May 2022, respectively. The Phase II dose expansion is targeted in the fourth quarter of 2022.

The Phase I dose escalation of JAB-21822 in combination with an anti-EGFR antibody cetuximab was completed in June 2022. The first patient for the Phase IIa dose expansion of JAB-21822 in combination with an anti-EGFR antibody cetuximab was treated in July 2022.

We have received the IND approval for JAB-21822 monotherapy Phase I/IIa trial in NSCLC patients with STK-11 co-mutation and the first patient is expected to be enrolled in September 2022.

PROGRESS OF OTHER PRODUCTS:

- **JAB-8263 (BET inhibitor)**

The first patient of the Phase I dose escalation portion in China for solid tumors was successfully dosed in February 2022.

- **JAB-2485 (Aurora A kinase inhibitor)**

We are in the process of launching a Phase I/IIa trial of JAB-2485 in the U.S. and China. In the U.S., we received the IND approval of JAB-2485 for a Phase I/IIa trial from the U.S. FDA in January 2022. In China, the IND application for a Phase I/IIa trial was submitted to the NMPA in August 2022.

- **JAB-BX102 (CD73 inhibitor)**

We have received the IND approval for Phase I trial in advanced solid tumors from the NMPA in March 2022.

Business Highlights

- **JAB-26766 (PARP7 inhibitor)**

JAB-26766 is an orally bioavailable small-molecule PARP7 inhibitor, targeting immuno-oncology pathway for the treatment of a variety of solid tumors. We remain on track to submit the IND application in the fourth quarter of 2022.

- **JAB-23400 (KRAS^{multi} inhibitor)**

JAB-23400 is a first-in-class, orally bioavailable, KRAS^{multi} inhibitor. It can potently inhibit the activity of multiple KRAS mutants in both RAS (ON) and RAS (OFF) states, including KRAS G12X (G12D, G12V, G12R, G12S and G12A), G13D and Q61H, with no inhibition of HRAS and NRAS. Tumor regression was achieved by oral administration in LS513 (KRAS G12D) and SW403 (KRAS G12V) models. The drug candidate was nominated in February 2022 and the IND application is expected to be submitted in 2023.

- **JAB-30300 (P53 Y220C inhibitor)**

JAB-30300 is an orally bioavailable small molecule for the treatment of patients with locally advanced or metastatic solid tumors harboring P53 Y220C mutation. The drug candidate was nominated in June 2022 and the IND application is expected to be submitted in 2023.

OUR iADC PROGRAMS:

- We have leveraged our strength in small-molecule drug discovery and development in designing innovative immune-stimulators as payloads and built our immunostimulatory antibody-drug conjugate (iADC) platform. Our novel iADC program using immune-stimulators, including Stimulator of Interferon Genes (STING) and other novel small-molecules, as payloads have the potential to address the challenges of both the toxicity caused by the conventional ADC and the low response rate in current immune-checkpoint inhibitors (ICIs) therapy.

Management Discussion and Analysis

OVERVIEW

Tremendous progress in cancer biology in the past several decades has elucidated several critical cellular pathways involved in cancer, including Kirsten rat sarcoma 2 viral oncogene homolog (KRAS), MYC proto-oncogene (MYC), P53 and Retinoblastoma (RB), as well as certain immune checkpoints such as programmed cell death protein-1 or its ligand (PD-(L)1) checkpoint and tumor metabolic pathway, that are implicated in more than 70% of total cancer incidence. However, many known targets in these pathways including protein tyrosine phosphatases (PTPs) like Src homology region 2 domain-containing phosphatase-2 (SHP2) and GTPases like KRAS, among others, that play crucial roles in tumorigenesis, have until recently been deemed “undruggable,” owing to a variety of drug discovery challenges.

We are a clinical-stage pharmaceutical company focusing on the in-house discovery and development of innovative oncology therapies. Established in July 2015, we are an explorer in developing clinical-stage small-molecule drug candidates to modulate enzymes by binding to their allosteric sites, i.e., sites other than the active site that catalyzes the chemical reaction, in order to address targets which are lack easy-to-drug pockets where drugs can bind. Besides, we are also developing novel candidates with new modalities, spanning from small molecule and monoclonal antibody to iADC and cell therapy.

We intend to proactively explore and enter into strategic and synergistic partnerships with leading multinational corporations (MNCs), as exemplified by the collaboration with AbbVie Ireland Unlimited Company (“**AbbVie**”), a wholly-owned subsidiary of AbbVie Inc. (NYSE: ABBV), for our innovative, allosteric SHP2 inhibitors. Such partnerships pool complementary expertise and resources to increase the chances of success for our drug candidates and ensure maximization of their clinical and commercial value on a global scale.

For details of any of the foregoing, please refer to the rest of this interim report, and, where applicable, the Prospectus and prior announcements published by our Company on the websites of the Stock Exchange and our Company.

OUR PRODUCTS AND PRODUCT PIPELINE

In the past six years, by leveraging our proprietary technologies and know-how in drug discovery and development, we have developed an innovative pipeline of drug candidates, including six assets in Phase I/II trials and several others at the IND-enabling stage. These drug candidates may have broad applicability across various tumor types and demonstrate combinatorial potential among themselves.

Management Discussion and Analysis

The following charts summarize our pipeline, the development status of each clinical candidate and selected IND-enabling stage candidates as of the date of this interim report.

Clinical stage candidates

Asset	Regimen	Indications	IND	Phase I	Phase II	Recent development	Upcoming Milestone (expected)
JAB-3312 SHP2 abbvie	Combo w/KRAS G12Ci	KRAS G12C mut NSCLC	Global trial +			Phase IIa initiated in Jul 2022	
	Combo w/EGFRi	Osimertinib progressed NSCLC	Global trial +			FPI in Jan 2022	
	Combo w/PD-1 mAb	NSCLC, HNSCC, ESCC	Global trial +			Phase IIa initiated with FPI in Feb 2022	
	Mono	BRAF class 3/ NF1 LOF mutant solid tumors	US and China trial *				
JAB-3068 SHP2 abbvie	Mono	ESCC, HNSCC, NSCLC, ACC	US and China trial				
	Combo w/PD-1 mAb	ESCC, HNSCC, NSCLC	China trial				
JAB-21822 KRAS G12C (RAS pathway)	Mono	NSCLC	China trial			Phase II initiated with FPI in Mar 2022	Pivotal trial expected to start in 2022 2H
	Mono	CRC, PDAC and other solid tumors	China trial			Phase IIa initiated with FPI in Mar 2022	
	Mono Combo w/EGFR mAb	NSCLC, CRC, PDAC	Global trial			FPI in May 2022 in Europe	Expansion portion to be initiated in 2022 2H
	Mono	NSCLC with STK-11 co-mutation	China trial				FPI (2022 Q3)
	Combo w/SHP2i	Advanced solid tumors	China trial +			FPI in May 2022	
	Combo w/EGFR mAb	CRC	China trial +			Phase IIa initiated with FPI in Jul 2022	
	Combo w/PD-1 mAb	NSCLC	China trial +				FPI (2023 1H)
JAB-8263 BET (MYC pathway)	Mono	Solid tumors	US trial				RP2D to be determined in 2022 Q4
	Mono	Solid tumors	China trial			FPI in Feb 2022	
	Mono Combo w/JAKi	MF and AML	China trial				
JAB-BX102 CD73 mAb (I/O)	Mono Combo w/PD-1 mAb	Solid tumors	Global trial			IND (NMPA) approved in Mar 2022	FPI (2022 Q3)
JAB-2485 Aurora A (RB pathway)	Mono	Solid tumors	Global trial			IND (FDA) approved in Jan 2022	FPI (2022 Q4)

Notes:

- *: We have initiated or will initiate Phase IIa study directly after RP2D is determined.
- + : We have initiated or will initiate Phase Ib/IIa studies directly once we receive IND approval.

Management Discussion and Analysis

Pre-clinical stage candidates

	Asset	Target	Modality	Lead optimization	Candidate IND-enabling	IND Schedule	Indications	Recent development
IND-Enabling	JAB-23400	KRAS ^{G12S} (RAS pathway)	Small molecule			2023	PDAC, CRC, NSCLC	Candidate nominated, entering into IND-enabling studies in Feb 2022
	JAB-30300	P53 Y220C (P53 pathway)	Small molecule			2023	Solid tumor	Candidate nominated, entering into IND-enabling studies in Jun 2022
	JAB-26766	PARP7 (I/O)	Small molecule			2022 Q4	Solid tumor	Candidate nominated, entering into IND-enabling studies in Jan 2022
	JAB-24114	Undisclosed (Tumor metabolic pathway)	Small molecule			2022 Q4	Solid tumor, Hematological malignancies	Candidate nominated, entering into IND-enabling studies in Mar 2021
	JAB-BX300	Undisclosed (RAS pathway)	Monoclonal antibody			2022 Q4	Solid tumor	Candidate nominated, entering into IND-enabling studies in Mar 2021
Lead Optimization	JAB-BX400	HER2 (I/O)	iADC			2024	Solid tumor	Payload has been selected and patent filed in Dec 2021
	JAB-X1800	CD73 (I/O)	iADC			2024	Solid tumor	Payload has been selected and patent filed in Dec 2021
	JAB-22000	KRAS G12D (RAS pathway)	Small molecule			2024	PDAC, CRC, NSCLC	Lead series identified and patent filed in Nov 2020

We believe there is tremendous potential for combinatorial strategy among our in-house pipeline assets. For instance, KRAS inhibitors can result in treatment resistance. Based on our pre-clinical studies and other publications, SHP2 inhibitors (upstream of the RAS pathway) may potentially be the ideal combinatorial partners for KRAS inhibitors to circumvent the adaptive drug resistance. Based on the strong rationale of the double blockade of SHP2 and KRAS G12C, we have prioritized the clinical development of SHP2 inhibitor plus KRAS G12C combination. In fact, the Phase I dose escalation of JAB-3312 and Sotorasib (KRAS G12C inhibitor, Amgen, U.S.) trial has been completed and the Phase IIa dose expansion was open for enrollment in the U.S. at the end of July 2022. In addition, the first patient in the combination trial of JAB-3312 and our KRAS G12 inhibitor JAB-21822 in China was dosed in May 2022.

BUSINESS REVIEW

Our Clinical Stage Drug Candidates

We made tremendous progress in clinical development of our assets in the first half of 2022. A total of seven new studies were initiated and first patient enrollments (FPIs) into those trials were achieved in the first half of 2022. Moreover, the Phase I/IIa dose escalation and expansion trial of the KRAS G12C inhibitor JAB-21822 monotherapy trial in China were completed. The preliminary data reported at the 2022 ASCO Annual Meeting showed that JAB-21822 has promising efficacy and a well-tolerated safety profile. The pivotal trial for JAB-21822 monotherapy in China will be launched in the second half of 2022.

- **JAB-3068 & JAB-3312**

Our lead drug development programs include two clinical-stage, oral allosteric SHP2 inhibitors (JAB-3068 and JAB-3312), for the potential treatment of cancers driven by RAS signaling pathway and immune checkpoint pathway. We believe SHP2 inhibition is a promising novel therapeutic approach either as a monotherapy or in combination with other therapies for treatment of multiple cancer types. JAB-3068 is the second SHP2 inhibitor received the IND approval from the U.S. FDA to enter clinical development. In the U.S., JAB-3068 and JAB-3312 have received an orphan drug designation from the U.S. FDA for the treatment of esophageal cancer. The current issued patents and published patent applications have already provided a broad scope of protection for SHP2 inhibitors, as the established players in this field have built a wall of the patent that is hard for any newcomers to circumvent, and therefore enlarged our first-mover advantages in the market. Key highlights of the SHP2 program over the Reporting Period are listed below.

Management Discussion and Analysis

o JAB-3312 in Combination with KRAS G12C Inhibitor/EGFR Inhibitor/anti-PD-1 Antibody/MEK Inhibitor

JAB-3312 in combination with KRAS G12C inhibitor

Global Study

We have completed the Phase I dose escalation for JAB-3312 combining with Sotorasib in July 2022.

The Phase IIa dose expansion portion in KRAS G12C treatment naïve NSCLC patients is ongoing.

China Study

The IND application for JAB-3312 in combination with JAB-21822 was approved by the NMPA in January 2022. A Phase I/IIa, open-label, multi-center, dose-escalation and expansion clinical trial in China was subsequently initiated to explore the safety, tolerability and preliminary efficacy of the combination therapy of JAB-3312 and JAB-21822 in advanced solid tumors with KRAS G12C mutation.

The first patient was successfully dosed in May 2022. The Phase I dose escalation is ongoing. Partial response was observed in the first NSCLC patient enrolled in the first dose level. Both KRAS G12C treatment for naïve and resistant patients will be enrolled in Phase IIa expansion stage in the fourth quarter of 2022.

JAB-3312 in combination with EGFR inhibitor

The global Phase I dose escalation for JAB-3312 in combination with osimertinib is ongoing. The early clinical response with confirmed PR was observed in one EGFR inhibitor resistant NSCLC patient.

JAB-3312 in combination with anti-PD-1 antibody or MEK inhibitor

We have initiated a global Phase Ib/IIa trial to evaluate JAB-3312 in combination with either pembrolizumab or binimetinib for patients with advanced solid tumors.

We had completed Phase I dose finding portion trial of JAB-3312 in combination with pembrolizumab in the U.S. The Phase IIa dose exploration is being carried out in China. Early clinical response was observed in patients with certain tumor types.

The Phase I dose escalation portion of JAB-3312 in combination with binimetinib is closed to enrollment.

o JAB-3312 and JAB-3068 Monotherapy

Monotherapy studies for both JAB-3312 and JAB-3068 have identified the maximum tolerated dose (MTD) and RP2D. In both U.S. and China, Phase I or Phase I/IIa trials in ESCC, HNSCC and NSCLC are closed to enrollment.

Management Discussion and Analysis

o JAB-3068 in Combination with anti-PD-1 antibody in China

The Phase I dose optimization for JAB-3068 in combination with anti-PD-1 antibody (JS-001) is in the final stage in China. We observed the clinical response in patients with certain tumor types. The Phase I study is expected to be completed by the end of this year.

o Collaboration with AbbVie

We have entered into a license and collaboration agreement with AbbVie to develop and commercialize our SHP2 inhibitors on a global basis in May 2020, including JAB-3068 and JAB-3312 (the “**SHP2 Products**”). Under the license and collaboration agreement, subject to our option (the “**PRC Option**”) to exclusively develop and commercialize our SHP2 inhibitors in China, Hong Kong and Macau (the “**Territory**”), which we exercised in September 2020, we have granted AbbVie a worldwide, exclusive, sublicensable license to research, develop, manufacture, commercialize and otherwise exploit our SHP2 inhibitors. As we have exercised the PRC Option, we have the exclusive rights (even as to AbbVie and its affiliates) to develop, commercialize and, if we elect to, manufacture such SHP2 Products to seek regulatory approval of and to commercialize in the Territory and, subject to limited exceptions, we are entitled to retain the final decision-making power, over all development, commercialization, manufacturing and regulatory activities to support regulatory approval of our SHP2 Products in the Territory.

This collaboration provides strong validation of our internally discovered SHP2 programs and ensures maximization of their medical and commercial value on a global scale.

For more details of our collaboration with AbbVie, please refer to the paragraphs headed “Business – III. Collaboration with AbbVie” of the Prospectus.

Warning under Rule 18A.08(3) of the Listing Rules: There is no assurance that the JAB-3312 and JAB-3068 will ultimately be successfully developed and marketed by our Company. Shareholders of our Company and potential investors are advised to exercise caution when dealing in the shares of our Company.

• JAB-21822

Our lead KRAS inhibitor candidate, JAB-21822, is a potent, selective and bioavailable small molecule targeting mutant KRAS G12C protein, and it has demonstrated promising pre-clinical antitumor activity either as a single agent or in combination with other anti-cancer drugs, such as SHP2 inhibitor, anti-EGFR antibody and anti-PD-1 antibody. In our internal head-to-head pre-clinical animal studies, JAB-21822 has shown a favorable pharmacokinetics (PK) profile and tolerability as well as the potential for a superior dosing profile in comparison with Amgen’s and Mirati’s KRAS G12C inhibitors (which we internally synthesized based on published molecular structures).

Management Discussion and Analysis

During the Reporting Period, we have achieved the following progress or milestones:

o JAB-21822 Monotherapy

China Study

In China, the Phase I dose escalation of JAB-21822 in patients with tumors harboring a KRAS G12C mutation was completed. 56 patients with advanced solid tumors harboring KRAS G12C mutation were enrolled in five dose level (QD, BID and TID regimen) within seven months, illuminating our robust clinical research and drug development capability.

In March 2022, multiple Phase II expansion cohorts were initiated, and as of July 31, 2022, a total of 50 NSCLC patients at the RP2D have been treated. Multiple cohorts are ongoing in parallel for CRC, PDAC and other solid tumor patients with KRAS G12C mutation. With the favorable efficacy and safety profile, the pivotal trial in patients with NSCLC harboring KRAS G12C mutation is expected to start in the second half of 2022.

Phase I preliminary clinical data of JAB-21822 monotherapy trial in China, particularly the NSCLC cohort, was reported at the 2022 ASCO Annual Meeting in June 2022, the details of which are set out as below:

- As of April 1, 2022, the Phase I clinical data of NSCLC patients with KRAS G12C mutation shows that the overall response rate (ORR) was 56.3% (18/32) and the disease control rate (DCR) was 90.6% (29/32). In 400mg QD and 800mg QD cohorts, the ORR was 66.7% (8/12) and the DCR was 100% (12/12). JAB-21822 was well tolerated with no DLTs in the dose escalation phase. The clinical trial is still ongoing and remains open to enrollment.

Global Study

The IND application of Phase I trial of JAB-21822 in patients with solid tumors harboring a KRAS G12C mutation in both monotherapy and in combination with anti-EGFR antibody cetuximab was approved by U.S. FDA in May 2021. Regulatory submissions in three European countries and Israel were also completed in 2021.

The first patient of monotherapy has been successfully dosed in September 2021 in the U.S. and in May 2022 in Europe, respectively. The Phase I dose escalation for JAB-21822 global study was completed in August 2022 and the Phase II dose expansion portion is expected to be initiated in the third quarter of 2022.

o JAB-21822 in Combination with anti-EGFR Antibody cetuximab in China

The IND application for JAB-21822 in combination with anti-EGFR antibody cetuximab was approved in China in December 2021. A Phase I/IIa, open-label, multi-center, dose-escalation and expansion clinical trial in China was initiated to explore the safety, tolerability and preliminary efficacy of the combination therapy of JAB-21822 and cetuximab in advanced colorectal cancer with KRAS G12C mutation.

The Phase I dose escalation was completed in June 2022. The first patient for Phase IIa dose expansion was treated in July 2022.

Management Discussion and Analysis

o JAB-21822 Monotherapy in NSCLC Patients with STK-11 Co-mutation in China

The IND application for JAB-21822 monotherapy in NSCLC patients with serine/threonine kinase 11 (STK-11) co-mutation was approved by the NMPA in October 2021. A Phase I/IIa, open-label, multi-center, dose-escalation and expansion clinical trial in China was initiated aiming to explore the safety, tolerability and preliminary efficacy. The clinical trial focuses on the first line NSCLC patient who have KRAS G12C and STK-11 co-mutation. The first patient for Phase I dose escalation is expected to be enrolled in September 2022.

o Combination Therapy with anti-PD-1 Antibody in China

The IND application for the Phase I/IIa trial of JAB-21822 in combination with anti-PD-1 antibody was approved by the NMPA in October 2021. We are optimizing clinical development strategy for JAB-21822 in combination with anti-PD-1 antibody to better position this combo therapy considering the current NSCLC treatment landscape and other KRAS G12C inhibitors' global approval status. The first patient is expected to be enrolled in the first half of 2023.

We will continue to proactively communicate with regulatory authorities in the respective major markets and pursue opportunities for expedited track of regulatory approval or designations with preferential treatment, such as breakthrough therapies. In addition, we have been exploring the potential synergistic combinations by working with potential, value-adding collaborators, and to maximize the clinical and commercial value of our drug candidates on a global scale.

Warning under Rule 18A.08(3) of the Listing Rules: There is no assurance that the JAB-21822 will ultimately be successfully developed and marketed by our Company. Shareholders of our Company and potential investors are advised to exercise caution when dealing in the shares of our Company.

• JAB-8263

Our JAB-8263 is an innovative, selective and potent small molecule inhibitor of BET family proteins, which plays a key role in tumorigenesis by controlling the expression of oncogenes such as c-Myc. We are evaluating JAB-8263 for the treatment of various solid tumors such as NMC, NSCLC, SCLC, CRPC, ESCC and ovarian cancer, and hematological malignancies such as MF and AML.

o Solid Tumors

The Phase I dose escalation is ongoing in the U.S. and China. The first patient was enrolled in the U.S. in November 2020. The first patient of Phase I dose escalation portion in China for solid tumors was successfully dosed in February 2022. By leveraging clinical data from both U.S. and China in real time, we expect to expedite the comprehensive assessment of drug safety, tolerability and preliminary efficacy on a global scale.

o MF and AML

The Phase I dose escalation of JAB-8263 in hematological malignancies in China is ongoing. The enrollment of the first patient in China was completed in April 2021.

To date, JAB-8263 has demonstrated favorable safety and tolerability comparing with other BET inhibitors in clinical development. RP2D is expected to be determined in the fourth quarter of 2022. Further expansion will be determined once RP2D is identified.

Management Discussion and Analysis

Warning under Rule 18A.08(3) of the Listing Rules: There is no assurance that the JAB-8263 will ultimately be successfully developed and marketed by our Company. Shareholders of our Company and potential investors are advised to exercise caution when dealing in the shares of our Company.

- **JAB-2485**

JAB-2485 is an oral highly selective small molecule Aurora A kinase inhibitor. JAB-2485 can inhibit Aurora A activity, induce apoptosis and inhibit tumor growth. As of the date of this interim report, there is no commercialized Aurora A inhibitor globally. Pre-clinical data show that JAB-2485 is a highly selective inhibitor, and the inhibitory activity of Aurora A is one thousand times higher than that of Aurora B. JAB-2485 may potentially benefit patients with RB loss tumors, such as small cell lung cancer and triple negative breast cancer.

We are in the process of launching a Phase I/IIa trial of JAB-2485 in the U.S. and China. We received the IND approval of JAB-2485 for a Phase I/IIa trial from the U.S. FDA in January 2022. Study startup activities are ongoing at several U.S. sites, and we expect to dose the first patient in the fourth quarter of 2022 in the U.S. Furthermore, this is the first global trial managed by our internal clinical team without oversea clinical CRO's support, which is also a milestone to demonstrate the global clinical development capacity and capability of our clinical team. In China, the IND application for a Phase I/IIa trial was submitted to the NMPA in August 2022.

Warning under Rule 18A.08(3) of the Listing Rules: There is no assurance that the JAB-2485 will ultimately be successfully developed and marketed by our Company. Shareholders of our Company and potential investors are advised to exercise caution when dealing in the shares of our Company.

- **JAB-BX102**

JAB-BX102 is a humanized monoclonal antibody against CD73, a key protein involved in the adenosine pathway. Combination of JAB-BX102 with immune checkpoint inhibitor such as anti-PD-(L)1 antibodies can result in synergistic anti-tumor effect. JAB-BX102 is our first large molecule program entered into clinical stage.

We received the IND approval for a Phase I/IIa trial of JAB-BX102 in advanced solid tumors from the U.S. FDA in October 2021 and the NMPA in March 2022, respectively. Study startup activities are ongoing, and we expect to enroll the first patient in China in the third quarter of 2022. Once the Phase I dose escalation stage is completed, U.S. patients will participate in the Phase IIa dose expansion for which they will receive the combination of JAB-BX102 and pembrolizumab.

Warning under Rule 18A.08(3) of the Listing Rules: There is no assurance that the JAB-BX102 will ultimately be successfully developed and marketed by our Company. Shareholders of our Company and potential investors are advised to exercise caution when dealing in the shares of our Company.

Our Pre-clinical Drug Candidates (Small Molecule or Monoclonal Antibody)

We have also developed a diverse pipeline of assets targeting various other major and critical pathways involved in cancer (including RAS, MYC, P53, RB, immuno-oncology and tumor metabolic pathways) and have demonstrated potential to be among the first few market entrants in their respective drug classes globally. These include potentially first-in-class and/or best-in-class innovative drug candidates against novel or validated targets. We will continue to advance the drug discovery and development of these portfolio assets in both China and the U.S. in parallel, and actively explore possible combinations amongst our own pipeline drug candidates.

Management Discussion and Analysis

- **Leading Pre-clinical Stage Drug Candidates**

- o **JAB-23400** – JAB-23400 is a first-in-class, orally bioavailable, KRAS^{multi} inhibitor. It can potentially inhibit the activity of multiple KRAS mutants in both RAS (ON) and RAS (OFF) states, including KRAS G12X (G12D, G12V, G12R, G12S and G12A), G13D and Q61H, with no inhibition of HRAS and NRAS.

In pre-clinical studies, JAB-23400 exhibited an acceptable oral bioavailability both in rodents and non-rodents species. JAB-23400 also showed an excellent anti-tumor effect in KRAS G12X (G12D, G12V, G12R, G12S and G12A), G13D, and Q61H mutant tumor xenografts. Tumor regression was achieved by oral administration in LS513 (KRAS G12D) and SW403 (KRAS G12V) models. According to the pre-clinical data, it is predicted that JAB-23400 will have an acceptable exposure on human.

The drug candidate was nominated in February 2022 and the IND application is expected to be submitted in 2023. To date, there is no small-molecule KRAS^{multi} inhibitor that targets both RAS (ON) and RAS (OFF) states in clinical stage globally. Therefore, JAB-23400 has the potential to be among the first few market entrants.

- o **JAB-30300** – JAB-30300 is an orally bioavailable small molecule for the treatment of patients with locally advanced or metastatic solid tumors harboring P53 Y220C mutation. JAB-30300 was nominated as clinical candidate in June 2022. It has shown favorable PK properties in different species and tumor regression was achieved in different CDX mice models.

IND application is expected to be submitted in 2023. Currently, there is only one program in the Phase I clinical stage in respective drug classes globally. Therefore, JAB-30300 has the potential to be among the first few market entrants.

- o **JAB-26766** – JAB-26766 is an orally bioavailable small-molecule PARP7 inhibitor, targeting immuno-oncology pathway for the treatment of a variety of solid tumors such as SCLC, HNSCC and ESCC. PARP7 acts as a brake in type I interferon (IFN) signaling in a TBK1-dependent manner. JAB-26766 has exhibited favorable in vitro cell inhibition activities and selectivity. Higher exposure in mice and dog was seen for JAB-26766 per oral administration which led to substantial tumor inhibition activities in different tumor models.

JAB-26766 is currently at the IND-enabling stage and the IND application is expected to be submitted in the fourth quarter of 2022. Currently, there is only one program in the Phase I clinical stage in respective drug classes globally, therefore JAB-26766 has the potential to be among the first few market entrants.

Warning under Rule 18A.08(3) of the Listing Rules: There is no assurance that the JAB-23400, JAB-30300 and JAB-26766 will ultimately be successfully developed and marketed by our Company. Shareholders of our Company and potential investors are advised to exercise caution when dealing in the shares of our Company.

Management Discussion and Analysis

• *Other Pre-clinical Stage Drug Candidates*

- o **JAB-24114** – JAB-24114 is targeting tumor metabolic pathway developed for the treatment of solid tumors including NSCLC and HNSCC. Tumor metabolism has emerged as a promising new field for cancer drug discovery. Through genetic mutations that alter fundamental metabolic pathways, tumor cells can acquire the ability to grow in an uncontrolled manner, but they also acquire dependencies that can differentiate them from normal cells. JAB-24114 can also be used in combination with SHP2 inhibitors or KRAS inhibitors. The first patent filing was made in May 2020. Currently there is only one program in the Phase I clinical stage in respective drug classes globally. Therefore, JAB-24114 has the potential to be among the first few market entrants. JAB-24114 is currently at the IND-enabling stage. We remain on track to submit an IND application for JAB-24114 in the fourth quarter of 2022.
- o **JAB-BX300** – JAB-BX300 is a large molecule antibody targeting RAS pathway for the treatment of pancreatic and other solid tumors with KRAS mutations. The first patent filing was submitted in September 2019. Currently there is only one program in the Phase I clinical stage in respective drug classes globally. Therefore, JAB-BX300 has the potential to be among the first few market entrants. JAB-BX300 is currently at the IND-enabling stage. We remain on track to submit an IND application for JAB-BX300 in the fourth quarter of 2022.
- o **JAB-22000** – JAB-22000 is a small-molecule KRAS G12D inhibitor. Lead series with high potency and selectivity have been identified and our first patent filing was made in November 2020. Subsequent patent filings have covered multiple directions. It is currently in lead optimization stage, targeting to submit the IND application in 2024. Currently there is no clinical stage small molecule KRAS G12D programs globally. Therefore, JAB-22000 has the potential to be among the first few market entrants.

Warning under Rule 18A.08(3) of the Listing Rules: There is no assurance that the JAB-24114, JAB-BX300 and JAB-22000 will ultimately be successfully developed and marketed by our Company. Shareholders of our Company and potential investors are advised to exercise caution when dealing in the shares of our Company.

Our iADC Programs

A growing body of ADCs are currently in clinical development, some of which had been approved by the U.S. FDA, verifying the concept of “magic bullet”. However, these conventional ADCs, which use toxins as payloads, have demonstrated obvious toxicity because the toxin molecules can be delivered to the normal tissues. These safety concerns limit the application of conventional ADCs. Meanwhile, checkpoint immunotherapies have revolutionized the field of cancer therapeutics, yet a substantial subset of patients fail to respond. A major factor involved in initial resistance to current ICIs is the lack of T cell infiltration into tumor, characterizing the so-called “cold tumor”. Immuno-stimulators can enhance the filtration of immune cells and turned the tumor from “cold” to “hot”.

We have leveraged our strength in small-molecule drug discovery and development in designing innovative immune-stimulators as payloads and built our iADC platform. Our novel iADC program using immune-stimulators, including STING and other novel small molecules as payloads have the potential to address the challenges of both the toxicity caused by the conventional ADC and the low response rate in current ICI therapy.

Management Discussion and Analysis

- ***STING-iADC Programs – Unique Payload to Support Multiple iADC Programs***

Recent efforts have been focused on identifying targets that could elicit or augment anti-tumor immune responses. One of such novel targets is STING, an endoplasmic protein that stimulates innate immune and turn “cold” tumor to “hot” by inducing the production of pro-inflammatory cytokines such as IFNs.

There are already multiple projects in clinical stage evaluating the efficacy and safety of either intratumoral injection or systemic administration of STING agonist. Although such approaches have shown many therapeutic benefits, including potent anti-tumor activity, the therapeutic window was limited by immune-related toxicity, such as cytokine release syndrome (CRS).

By specifically delivering highly potent STING agonist into tumor associated antigen (TAA) expressing tumor cell, rationale designed iADC could locally activate anti-tumor activity to boost the tumor specific innate/adaptive immune response and avoid the risk of systemic immune-related adverse effect.

JAB-27670 is a highly potent novel non-cyclic dinucleotide (non-CDN) small-molecule STING agonist designed with sub-nanomolar activity, which is suitable to be used as payload through our internal evaluation. It has exhibited a potent and durable tumor inhibition in CT26 and MC38 CDX models at a low dose (0.6 mg/kg, Q3D) and was validated in HER2 and CD73 targets internally.

- o ***JAB-BX400 (a STING-iADC product candidate targeting HER2)***

By using JAB-27670 as payload, we have developed our in-house HER2-STING iADC (JAB-BX400). HER2, also known as ERBB-2 or neu, is a protein tyrosine kinase receptor encoded on chromosome 17q12. High HER2 expression can lead to the enhanced proliferation of various malignant tumor cells. Our HER2-STING iADC showed excellent features in pre-clinical studies, including favorable physicochemical properties at even high drug to antibody ratio value, hundreds to thousands fold improvement in activity over the free STING payload, and complete and durable tumor regression with only single dose (1 mg/kg) in SK-OV-3 CDX model.

Based on the excellent in vivo efficacy of our HER2-STING iADC, we are planning to nominate a candidate in the fourth quarter of 2022. IND application is expected to be submitted in 2024.

- o ***JAB-X1800 (a STING-iADC product candidate targeting CD73)***

By using JAB-27670 as payload, we have developed our in-house CD73-STING iADC (JAB-X1800). CD73 has emerged as a negative regulator of cancer immunity, which is thought to involve its enzyme product adenosine, an immunosuppressive molecule that can act on numerous immune-effector cells and suppressor cells. Our anti-CD73 antibody (JAB-BX102) can strongly inhibit CD73 enzyme activity and improves tumor immune microenvironment.

We are developing a novel iADC connecting JAB-BX102 and JAB-27670 with a cleavable linker, which could deliver the potent STING agonist into CD73-expressing tumor cell specifically and inhibit CD73 function as well. The strategy of double stimulation of immunity in tumor microenvironment (TME) could be a promising monotherapy or combination approach for cancer therapy.

JAB-X1800 is in lead optimization stage and IND application is expected to be submitted in 2024.

Management Discussion and Analysis

Warning under Rule 18A.08(3) of the Listing Rules: There is no assurance that our iADC Platform, JAB-BX400 and JAB-X1800 will ultimately be successfully developed and marketed by our Company. Shareholders of our Company and potential investors are advised to exercise caution when dealing in the shares of our Company.

CORPORATE DEVELOPMENT

We have a solid patent portfolio to protect our drug candidates and technologies. As of June 30, 2022, we owned 228 patents or patent applications that are filed globally, of which 37 patents have been issued or allowed in major markets globally.

IMPACT OF THE COVID-19 OUTBREAK

The management of our Company expected that clinical trials in and outside mainland China will not be significantly affected by the outbreak of COVID-19. Since the outbreak, we have deployed various measures to mitigate any impact the COVID-19 pandemic may have on our business, especially our ongoing clinical trials. We have endeavored to provide a safe work environment and adopted a thorough disease prevention scheme to protect our employees. There remains uncertainty regarding the future impact of the pandemic globally. Our Company is striving to minimize delays and disruptions and we believe that the COVID-19 pandemic did not significantly and materially affect our operation. However, the potential negative impact on our global operations in the future, including clinical trial recruitment and participation and regulatory interactions, may be difficult to predict.

FUTURE AND OUTLOOK

We are a front runner in selecting, discovering and developing potential first-in-class therapies with innovative mechanisms for global oncology treatment. By continuing to strengthen our drug discovery platform and to advance our pipeline, we expect to obtain global market leadership with a number of transforming therapies and expect to benefit cancer patients significantly. In addition, we also plan to add world-class manufacturing and commercialization capabilities to our integrated discovery and development platform as we achieve clinical progress and anticipate regulatory approvals.

In the near term, we plan to focus on pursuing the following significant opportunities:

- **Develop our SHP2 assets in China and worldwide**

We are one of the early movers globally in developing allosteric drugs, including two lead assets – SHP2 inhibitors and KRAS G12C inhibitor, which we expect to be the key revenue drivers. By executing the global clinical development plan in an efficient and timely manner, we believe that we can establish our SHP2 inhibitors as backbone drugs for multiple solid tumors.

In addition, as we have both SHP2 and KRAS assets in our pipeline, we are well-positioned to explore the clinical benefits of this combination therapy.

- **Develop, commercialize and expand our KRAS portfolio**

KRAS is one of the most well-known proto-oncogenes and is crucially involved in human cancer. Based on our cutting-edge allosteric inhibitor platform, we have developed a diversified portfolio of KRAS inhibitor programs that target different forms of KRAS which harbor either G12C, G12D, G12V or other mutations.

Management Discussion and Analysis

We plan to initiate the KRAS G12C inhibitor pivotal registrational trial in NSCLC in the second half of 2022 in China and expect to complete a new drug application (NDA) submission to the NMPA during the period from 2023 to 2024.

We intend to pursue the development of our frontier KRAS portfolio designed to address tumors where few treatment options exist with significant unmet medical needs in global market, including pancreatic, CRC and other solid tumors with KRAS mutations, in both single agent and rational combination therapies.

- **Develop our P53 portfolio**

P53 is the single most frequently altered gene in human cancers, with mutations being present in approximately 50% of all invasive tumors. We are leveraging our allosteric inhibitor platform to design and develop a pipeline of selective, small molecule, tumor-agnostic therapies that structurally correct specific mutant P53 proteins to restore their wild-type function. Currently, we are developing JAB-30300 for specific P53 Y220C mutations. At the same time, projects targeting P53 mutations other than Y220C are also under development to provide more effective treatment options.

- **Advance our iADC programs with unique payload**

Check point immunotherapies have revolutionized the field of cancer therapeutics, yet a substantial subset of patients fail to respond. We have identified a superior STING agonist that is suitable to be used as a payload by leveraging our expertise in developing small molecule drugs. Other than STING-iADC, an in-house iADC platform with unique immune-stimulators as payloads is under development to address the challenges with high unmet needs.

- **Continuously progress and expand the additional pipeline targeting multiple other promising pathways**

We have an established track record of successfully selecting important yet often overlooked or passed-over cancer targets. In addition to our SHP2 and KRAS assets, we will continue to progress our rich pipeline including several early-stage drug candidates that target a variety of other major and critical pathways and to explore possible combinations amongst our own pipeline drug candidates.

- **Capture global market opportunities and expand to compelling area of research through collaborations**

On the coattails of our landmark collaboration with AbbVie for our SHP2 portfolio inhibitors, we plan to continue exploring partnerships around the world to fulfill people's shared dream of curing cancer and living a better life. We intend to find the most suitable and resourceful partners for collaboration to expand our footprint of global development and the commercialization of our drug candidates. We will continue exploring partnerships around the world to look for compelling areas of research that have been primarily out of reach for many of the world's patients.

- **Strengthen our talent pool and increase multi-regional presence**

In order to execute our global development strategy, we have established dual R&D centers in both Beijing, China and Massachusetts, the U.S. as our two main global R&D hubs. Besides, we launched our third R&D center in Shanghai, China, to attract and recruit well-trained scientists and physicians around the world.

Management Discussion and Analysis

Our clinical development team has expanded its global footprint with clinical networks in China, the U.S. and Europe and is expected to expand to other territories in the near future. Our global clinical development capabilities are well demonstrated by our rapid implementation of over twenty ongoing clinical trials, including multi-regional clinical trials following specific regulatory requirements.

We have developed a cohesive and vibrant corporate culture that inspires and encourages innovation, which we believe helps us to attract, retain and motivate an aspiring team to drive our fast growth. We are committed to exploring cutting-edge anti-cancer therapies, with this belief, we plan to enrich our scientific teams in both China and the U.S.

- **Enhance our advanced research and development platform**

We have built an integrated R&D platform to enable our strategic focus on the R&D of innovative drugs in oncology with large unmet medical needs. Our integrated R&D platform consists of three specialized platforms, including a drug target discovery and validation platform, an allosteric inhibitor technology platform and a translational medicine platform.

We believe that R&D is key to driving our therapeutic strategy and maintaining our competitiveness in the biopharmaceutical industry. With this belief, we are committed to further strengthening and advancing our R&D platforms to continuously fuel innovation.

- **Expand our manufacturing capabilities in China**

We are building our in-house GMP-compliant manufacturing facilities to expand our manufacturing capabilities. We cooperate with a third party to construct new facilities for R&D, manufacturing and general administration with a total gross floor area of around 20,000 sq.m. in Beijing, China. The commercial-scale manufacturing facilities are currently under construction. It is estimated that the construction and fit-out of the manufacturing facilities will be completed by the end of 2023.

We are committed to being an innovative biopharmaceutical company which enjoys global market shares. To achieve this goal, we plan to build a fully functional capabilities including R&D, manufacturing and commercialization in China, and obtain global market shares by partnering with top MNCs. We strive to deploy our innovation engine for creating a robust pipeline in the fight against cancer for the benefits of patients around the world.

Management Discussion and Analysis

FINANCIAL REVIEW

Revenue

	Six months ended June 30,	
	2022	2021
	<i>RMB'000</i>	<i>RMB'000</i>
Revenue from the license and collaboration agreement	<u>54,687</u>	<u>57,689</u>

For the six months ended June 30, 2022 and 2021, our Group recorded revenue of RMB54.7 million and RMB57.7 million, respectively, which are in connection with the R&D costs reimbursement generated from the license and collaboration agreement with AbbVie regarding the R&D, manufacture and commercialization of our SHP2 inhibitors.

Cost of Revenue

	Six months ended June 30,	
	2022	2021
	<i>RMB'000</i>	<i>RMB'000</i>
Clinical trial expenses of our SHP2 inhibitors	<u>45,854</u>	<u>53,133</u>

Our cost of revenue consisted of research and development expenses related to our SHP2 inhibitors. For the six months ended June 30, 2022, we recorded cost of revenue of RMB45.9 million, mainly attributable to the clinical trial expenses of our SHP2 inhibitors, as compared with RMB53.1 million for the six months ended June 30, 2021.

Gross Profit

	Six months ended June 30,	
	2022	2021
	<i>RMB'000</i>	<i>RMB'000</i>
Gross profit from the license and collaboration agreement	<u>8,833</u>	<u>4,556</u>

As a result of the foregoing, our gross profit increased from RMB4.6 million for the six months ended June 30, 2021 to RMB8.8 million for the six months ended June 30, 2022.

Management Discussion and Analysis

Other Income

	Six months ended June 30,	
	2022 RMB'000	2021 RMB'000
Other income from a related party	1,284	–
Government grants	495	3,624
Total	1,779	3,624

Our Group's other income decreased from RMB3.6 million for the six months ended June 30, 2021 to RMB1.8 million for the six months ended June 30, 2022, primarily attributable to a decrease in government grants of RMB3.1 million.

Other Gains/(Losses) – Net

	Six months ended June 30,	
	2022 RMB'000	2021 RMB'000
Net foreign exchange gains/(losses)	49,154	(14,631)
Fair value changes on long-term investments measured at fair value through profit or loss	3,623	–
Net fair value gains on derivative financial instruments	565	2,701
Total	53,342	(11,930)

The increase in other gains was primarily attributable to the appreciation of USD and HKD for the six months ended June 30, 2022 which has resulted in net foreign exchange gains of RMB49.2 million for the six months ended June 30, 2022.

Our other gains and losses consisted primarily of gains or losses due to fluctuations in the exchange rates between RMB and USD and between RMB and HKD. Our net foreign exchange gains and losses increased by RMB63.8 million from losses of RMB14.6 million for the six months ended June 30, 2021 to gains of RMB49.2 million for six months ended June 30, 2022, which was mainly attributable to foreign exchange gains in connection with bank balances denominated in USD and HKD and the appreciation of USD and HKD against RMB for the six months ended June 30, 2022, compared to the depreciation of USD and HKD against RMB for the six months ended June 30, 2021.

Our business mainly operates in the PRC, and most of our Group's transactions are settled in RMB. Since our inception, we have financed our business solely through equity financings, with related proceeds denominated in USD, HKD and RMB. We converted a portion of those proceeds in USD and HKD to RMB with the remaining amounts reserved for additional conversions to RMB as needed. Translation of our monetary assets and liabilities at the period end exposes us to currency-related gains or losses and the actual conversion of our USD and HKD denominated bank balances will also expose us to currency exchange risk.

We have managed our foreign exchange risk by closely reviewing the movement of the foreign currency rates and would consider hedging against foreign exchange exposure should the need arise.

Management Discussion and Analysis

Research and Development Expenses

	Six months ended June 30,	
	2022 RMB'000	2021 RMB'000
Testing fee	65,197	51,994
Employee benefits expenses	55,785	38,184
Raw material and consumables used	37,780	18,985
Depreciation and amortization	4,914	3,765
Others	12,913	8,732
Total	176,589	121,660

Our research and development expenses increased by RMB54.9 million from RMB121.7 million for the six months ended June 30, 2021 to RMB176.6 million for the six months ended June 30, 2022, primarily due to (i) the advancement to our clinical candidates; (ii) expansion of pre-clinical research portfolio associated R&D activities; and (iii) the increased staff costs accompanied with expanding of relative R&D departments. Such increase in research and development expenses was resulted from the following factors:

- RMB18.8 million increase in raw material and consumables used due to the development of our drug candidates;
- RMB17.6 million increase in employee benefits expenses primarily due to an increase in the number of research and development employees and their salary level; and
- RMB13.2 million increase in testing fee mainly due to the rapid progress of the clinical trials and advancement of our pre-clinical drug candidates.

Administrative Expenses

	Six months ended June 30,	
	2022 RMB'000	2021 RMB'000
Employee benefits expenses	15,206	12,379
Professional services expenses	1,743	961
Depreciation and amortization	767	308
Others	5,063	4,880
Total	22,779	18,528

Our administrative expenses increased by RMB4.3 million from RMB18.5 million for the six months ended June 30, 2021 to RMB22.8 million for the six months ended June 30, 2022, which was primarily attributable to the increase of employee benefits expenses and other administrative expenses in line with our business expansion.

Management Discussion and Analysis

Finance Income

Our finance income increased by RMB0.1 million from RMB7.6 million for the six months ended June 30, 2021 to RMB7.7 million for the six months ended June 30, 2022, which was mainly attributable to the net impact of (i) increased average interest rate of time deposit during the six months ended June 30, 2022 compared to that for the six months ended June 30, 2021; and (ii) decreased interest income due to the decreased bank balances in line with our business progress.

Income Tax Expense

We recognized no income tax expenses for the six months ended June 30, 2021 and 2022.

Non-IFRS Measure

To supplement the consolidated financial statements, which are presented in accordance with the International Financial Reporting Standards (“**IFRS**”), our Company also uses adjusted loss for the Reporting Period and other adjusted figures as additional financial measures, which are not required by, or presented in accordance with, the IFRS. Our Company believes that these adjusted measures provide useful information to the Shareholders and potential investors in understanding and evaluating our Group’s consolidated results of operations in the same manner as they help our Company’s management.

Adjusted loss for the Reporting Period represents the loss for the Reporting Period excluding the effect of certain noncash items and one-time events, namely share-based payment expenses, fair value gains in derivative financial instruments arising from the commitment of investments and fair value gains in long-term investments measured at fair value through profit or loss. The term adjusted loss for the Reporting Period is not defined under the IFRS. The use of this non-IFRS measure has limitations as an analytical tool, and should not consider it in isolation from, or as substitute for analysis of, our Group’s results of operations or financial condition as reported under IFRS. Our Company’s presentation of such adjusted figure may not be comparable to a similarly titled measure presented by other companies. However, our Company believes that this and other non-IFRS measures are reflections of our Group’s normal operating results by eliminating potential impacts of items that the management do not consider to be indicative of our Group’s operating performance, and thus, facilitate comparisons of operating performance from period to period and from company to company to the extent applicable.

Management Discussion and Analysis

The table below sets forth a reconciliation of the loss to adjusted loss during the periods indicated:

	Six months ended June 30,	
	2022	2021
	RMB'000	<i>RMB'000</i>
Loss for the period	(127,825)	(136,597)
Added:		
Share-based payment expenses	6,488	10,829
Subtracted:		
Fair value gains in long-term investments measured at fair value through profit or loss	(3,623)	–
Fair value gains in derivative financial instruments arising from the commitment of investments	(3,456)	–
Adjusted loss for the period	(128,416)	(125,768)

The table below sets forth a reconciliation of the research and development expenses to adjusted research and development expenses during the periods indicated:

	Six months ended June 30,	
	2022	2021
	RMB'000	<i>RMB'000</i>
Research and development expenses for the period	(176,589)	(121,660)
Research and development expenses in relation to our SHP2 inhibitors which was recorded in Cost of Revenue for the period	(45,854)	(53,133)
Added:		
Share-based payment expenses	3,896	7,782
Adjusted research and development expenses for the period	(218,547)	(167,011)

The table below sets forth a reconciliation of the administrative expenses to adjusted administrative expenses during the periods indicated:

	Six months ended June 30,	
	2022	2021
	RMB'000	<i>RMB'000</i>
Administrative expenses for the period	(22,779)	(18,528)
Added:		
Share-based payment expenses	2,592	3,047
Adjusted administrative expenses for the period	(20,187)	(15,481)

Management Discussion and Analysis

Cash Flows

During the six months ended June 30, 2022, net cash used in operating activities of our Group amounted to RMB111.8 million, representing a decrease of RMB3.0 million compared to the net cash used in operating activities during the six months ended June 30, 2021. The decrease was mainly due to the cash used in our operating activities which was offset by the increase of interest received during the six months ended June 30, 2022.

During the six months ended June 30, 2022, net cash flows used in investing activities of our Group amounted to RMB1.7 million, representing an increase of RMB183.8 million over the net cash flows generated from investing activities of RMB182.1 million during the six months ended June 30, 2021. The increase was mainly due to the combined impact of (i) settlement of deposits with original maturities of over 3 months of RMB194.9 million during the six months ended June 30, 2021; and (ii) the purchase of long-term investments measured at fair value through profit or loss of RMB5 million during the six months ended June 30, 2022.

During the six months ended June 30, 2022, net cash flows used in financing activities of our Group amounted to RMB3.0 million, representing an increase of RMB122.6 million over the net cash flows generated from financing activities of RMB119.6 million during the six months ended June 30, 2021. The increase was mainly due to the impact of fund raised from the exercise of over-allotments option of RMB132.8 million during the six months ended June 30, 2021.

Significant Investments, Material Acquisitions and Disposals

During the six months ended June 30, 2022, our Group did not have any significant investments or material acquisitions or disposals of subsidiaries, associates, and joint ventures.

Liquidity, Capital Resources and Gearing Ratio

We expect our liquidity requirements will be satisfied by a combination of cash generated from operating activities, bank credits, funds raised from the capital markets from time to time and the net proceeds from the initial public offering.

We currently have bank credits of RMB100.0 million and do not have any plan for material additional equity financing. We will continue to evaluate potential financing opportunities based on our need for capital resources and market conditions.

As at June 30, 2022, our cash and bank balances were RMB1,466.6 million, as compared to RMB1,537.6 million as at December 31, 2021.

The decrease was mainly due to net cash used in our operating activities. Our primary uses of cash are to fund research and development efforts of new drug candidates, working capital and other general corporate purposes. Our cash and cash equivalents are held in USD, RMB and HKD.

Currently, our Group follows a set of funding and treasury policies to manage our capital resources and mitigate potential risks involved.

As at June 30, 2022, our Group did not have any interest-bearing bank and other borrowings. Thus, neither the gearing ratio nor the debt-to-equity ratio was applicable to our Group.

Management Discussion and Analysis

Lease Liabilities

IFRS 16 has been consistently applied to our Group's consolidated financial statements for the six months ended June 30, 2022 and for the year ended December 31, 2021. As at June 30, 2022, our lease liabilities amounted to RMB3.9 million.

Capital Commitments

As at June 30, 2022, our Group had capital commitments contracted for but not yet provided of RMB155.2 million, among which RMB4.2 million was in relation to contracts for purchase of property, plant and equipment and RMB151.0 million was primarily in relation to the capital commitments for the share purchase agreement entered into with Hebecell in August 2021.

As at December 31, 2021, our Group had capital commitments contracted for but not yet provided of RMB152.2 million, among which RMB3.8 million was in relation to contracts for purchase of property, plant and equipment and RMB148.4 million was primarily in relation to the capital commitments for the share purchase agreement entered into with Hebecell in August 2021. For details, please refer to the announcement published on the websites of the Stock Exchange and our Company dated August 31, 2021.

Contingent Liabilities

As at June 30, 2022, our Group did not have any contingent liabilities (December 31, 2021: Nil).

Pledge of Assets

There was no pledge of our Group's assets as at June 30, 2022.

Foreign Exchange Exposure

Our financial statements are expressed in RMB, but certain of our cash and cash equivalents, time deposits, contract assets, trade payables and other payables and accruals are denominated in foreign currencies, and are exposed to foreign currency risk. The management continuously monitors foreign exchange exposure and will consider hedging significant foreign currency exposure should the need arise.

Liquidity Risk

As at June 30, 2022, we recorded net current assets of RMB1,442.6 million, representing the decrease of RMB116.3 million from RMB1,558.9 million as at December 31, 2021. In the management of the liquidity risk, our Company monitors and maintains a level of cash and cash equivalents deemed adequate by our management to finance the operations and mitigate the effects of fluctuations in cash flows.

Management Discussion and Analysis

Employees and Remuneration Policies

As at June 30, 2022, we had 285 employees in total. The total remuneration costs amounted to RMB78.4 million for the six months ended June 30, 2022, as compared to RMB59.3 million for the six months ended June 30, 2021. The increase reflected the increased number of employees and their salary level which is in line with our business expansion.

In order to maintain the quality, knowledge and skill levels of our workforce, we provide continuing education and training programs, including internal and external training, for our employees to improve their technical, professional or management skills. We also provide training programs to our employees from time to time to ensure their awareness and compliance with our policies and procedures in various aspects.

We provide various incentives and benefits for our employees. We offer competitive salaries, bonuses and share-based compensation to our employees, especially key employees. We have made contributions to social security insurance funds (including pension plans, medical insurance, work-related injury insurance, unemployment insurance and maternity insurance) and housing funds for our employees in accordance with applicable laws. We have also adopted the 2021 Stock Incentive Plan on August 31, 2021, which intends to attract and retain the best available personnel, to provide additional incentives to employees and to promote the success of our Company's business. For more details of the 2021 Stock Incentive Plan, please refer to the announcements published on the websites of the Stock Exchange and our Company dated August 31, 2021 and October 8, 2021.

Supplementary Information

INTERIM DIVIDEND

The Board has resolved not to recommend any interim dividend for the six months ended June 30, 2022 (six months ended June 30, 2021: nil).

COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

Our Group is committed to implementing high standards of corporate governance to safeguard the interests of the Shareholders and enhance the corporate value as well as the responsibility commitments. Our Company has adopted the CG Code set out in Appendix 14 to the Listing Rules as our own code of corporate governance.

The Board is of the view that our Company has complied with all applicable code provisions of the CG Code for the six months ended June 30, 2022 and up to the date of this interim report, except for a deviation from the code provision C.2.1 of the CG Code as described below.

Under code provision C.2.1 of the CG Code, the responsibility between the chairman and chief executive should be separate and should not be performed by the same individual. However, Dr. Wang is the chairman of our Board and the chief executive officer of our Company. With extensive experience in the pharmaceutical industry and having served in our Company since its establishment, Dr. Wang is in charge of overall strategic planning, business direction and operational management of our Group. The Board considers that vesting the roles of chairman and chief executive officer in the same person is beneficial to the management of our Group. The balance of power and authority is ensured by the operation of the Board and our Company's senior management, which comprises experienced and diverse individuals. The Board currently comprises three executive Directors, three non-executive Directors and three independent non-executive Directors, and therefore has a strong independence element in its composition.

The Board will continue to review and monitor the practices of our Company with an aim of maintaining a high standard of corporate governance.

MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS

Our Company has adopted the Model Code set out in Appendix 10 to the Listing Rules as our code for dealing in securities in our Company by the Directors. The Directors have confirmed compliance with the required standard set out in the Model Code for the six months ended June 30, 2022 and up to the date of this interim report. No incident of non-compliance by the Directors was noted by our Company during the Reporting Period.

REVIEW OF FINANCIAL STATEMENTS AND INTERIM REPORT BY THE AUDIT COMMITTEE

Our Company has established an Audit Committee in compliance with Rules 3.21 and 3.22 of the Listing Rules and principle D.3 of the CG Code, and has adopted written terms of reference. The Audit Committee consists of one non-executive Director, Dr. Te-li Chen, and two independent non-executive Directors, Dr. Ge Wu and Dr. Daqing Cai. The Audit Committee is currently chaired by Dr. Daqing Cai, who possesses suitable professional qualifications.

The Audit Committee has discussed with our Company's management and reviewed the unaudited interim financial statements of our Group for the Reporting Period and this interim report. The Audit Committee considered that the interim results and this interim report are in compliance with the applicable accounting standards, laws and regulations, and our Company has made appropriate disclosures thereof.

Supplementary Information

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES OF OUR COMPANY

Neither our Company nor any of its subsidiaries had purchased, sold or redeemed any of our Company's listed securities during the six months ended June 30, 2022.

FUTURE PLANS FOR MATERIAL INVESTMENTS AND CAPITAL ASSETS

Save as disclosed in this interim report, we do not have other plans for material investments and capital assets.

CHANGES IN THE BOARD AND THE DIRECTORS' INFORMATION

Each of Dr. Shaojing HU (“**Dr. Hu**”), Dr. Ting FENG (“**Dr. Feng**”) and Dr. Xiaoming WU (“**Dr. Wu**”) has resigned from their positions as an executive Director, a non-executive Director and an independent non-executive Director, respectively, with effect from March 22, 2022. Accordingly, Dr. Wu has ceased to be a member of the nomination committee since March 22, 2022. Dr. Ge WU, an independent non-executive Director, has been appointed as a member of the nomination committee in place of Dr. Wu with effect from March 22, 2022. For more information, please refer to the announcement of our Company dated March 22, 2022.

Dr. Ge WU, our independent non-executive Director, has been appointed as a member of the nomination committee with effect from March 22, 2022.

Dr. Ge WU has been the independent director of Vats Liquor Chain Store Management Joint Stock Co., Ltd. (華致酒行連鎖管理股份有限公司) (a company listed on the Shenzhen Stock Exchange (stock code: 300755)) since April 2022.

Save for the above, during the Reporting Period, there was no change in the Board and the information of Directors which is required to be disclosed pursuant to Rule 13.51B(1) of the Listing Rules.

CONTINUING DISCLOSURE OBLIGATION PURSUANT TO THE LISTING RULES

Save as disclosed in this interim report, our Company does not have any other disclosure obligations under Rules 13.20, 13.21 and 13.22 of the Listing Rules.

DIRECTORS' AND CHIEF EXECUTIVES' INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES OF OUR COMPANY OR ITS ASSOCIATED CORPORATIONS

As at June 30, 2022, the interests and short positions of the Directors and the chief executives of our Company in the Shares, underlying Shares and debentures of our Company or its associated corporation (within the meaning of Part XV of the SFO) which were required to be entered in the register kept by our Company pursuant to section 352 of the SFO, or which were otherwise required, to be notified to our Company and the Stock Exchange pursuant to the Model Code, are set out below:

Supplementary Information

Interests in Shares of our Company

Name of Director	Nature of Interest	Number of Shares ⁽¹⁾	Approximate percentage of shareholding ⁽²⁾
Dr. Yinxiang Wang	Interest in controlled corporation; interest held jointly with another person	223,483,650 ⁽³⁾	28.97%
Ms. Xiaojie Wang	Beneficial owner; founder of a discretionary trust; interest held jointly with another person	223,483,650 ⁽⁴⁾	28.97%
Ms. Yunyan Hu	Beneficial owner; founder of a discretionary trust; interest held jointly with another person	223,483,650 ⁽⁵⁾	28.97%

Notes:

- All interests stated are long positions.
- The calculation is based on the total number of 771,462,180 Shares in issue as at June 30, 2022.
- The entire share capital of each of Dr. Wang's SPV 1 and Dr. Wang's SPV 2 is directly owned by Dr. Wang and indirectly wholly owned by Dr. Wang and Ms. Zhu Shen, the spouse of Dr. Wang, respectively, and the voting rights of the Shares held by Willgenpharma Ltd which are intended to be used for employee incentive purposes are exercisable by Dr. Wang. Accordingly, Dr. Wang is deemed to be interested in such number of Shares held by Dr. Wang's SPV 1, Dr. Wang's SPV 2 and Willgenpharma Ltd. Dr. Wang is also deemed to be interested in all Shares held by Wordspharma Ltd, a company wholly-owned by Ms. Zhu Shen as Ms. Zhu Shen is the spouse of Dr. Wang. In addition, each of Dr. Wang, Dr. Wang's SPV 1, Dr. Wang's SPV 2 and Willgenpharma Ltd is also deemed to be interested in all Shares held by Ms. Wang, Ms. Wang's SPV, Gloryviewpharma Ltd, Blesspharma Ltd, Honourpharma Ltd, Ms. Hu and Ms. Hu's SPV as they are parties acting in concert.
- The share capital of Ms. Wang's SPV is indirectly owned by the XM Family Trust as to 99.5% and directly owned by Ms. Wang as to 0.5%. Ms. Wang is the settlor, the protector and the beneficiary of the XM Family Trust and therefore she is deemed to be interested in the shares held by Ms. Wang's SPV under the SFO. The voting rights of the Shares held by Gloryviewpharma Ltd which are intended to use for employee incentive purposes are exercisable by Ms. Wang. Accordingly, Ms. Wang is deemed to be interested in the Shares held by Gloryviewpharma Ltd. In addition, each of Ms. Wang, Ms. Wang's SPV and Gloryviewpharma Ltd are deemed to be interested in all Shares held by Dr. Wang, Dr. Wang's SPV 1, Dr. Wang's SPV 2, Willgenpharma Ltd, Honourpharma Ltd, Blesspharma Ltd, Ms. Hu and Ms. Hu's SPV as they are parties acting in concert.
- The share capital of Ms. Hu's SPV is indirectly owned by the YN Family Trust as to 99.5% and directly owned by Ms. Hu as to 0.5%. Ms. Hu is the settlor, the protector and the beneficiary of the YN Family Trust and therefore she is deemed to be interested in the shares held by Ms. Hu's SPV under the SFO. In addition, each of Ms. Hu and Ms. Hu's SPV is deemed to be interested in all Shares held by Dr. Wang, Dr. Wang's SPV 1, Dr. Wang's SPV 2, Willgenpharma Ltd, Honourpharma Ltd, Ms. Wang, Ms. Wang's SPV, Gloryviewpharma Ltd and Blesspharma Ltd as they are parties acting in concert.

Save as disclosed above, as at June 30, 2022, none of the Directors and chief executives of our Company had any interests or short positions in the Shares, underlying Shares and debentures of our Company or its associated corporations, recorded in the register required to be kept under section 352 of the SFO or required to be notified to our Company and the Stock Exchange pursuant to the Model Code.

Supplementary Information

SUBSTANTIAL SHAREHOLDERS' AND OTHER PERSONS' INTERESTS AND SHORT POSITIONS IN THE SHARES AND UNDERLYING SHARES OF OUR COMPANY

So far as is known to our Company, as at June 30, 2022, as recorded in the register required to be kept by our Company under section 336 of the SFO, the following persons, other than a Director or chief executive of our Company, had an interest of 5% or more in the Shares or underlying Shares:

Name of Shareholder	Nature of Interest	Number of Shares ⁽¹⁾	Approximate percentage of shareholding ⁽²⁾
Dr. Wang ⁽³⁾	Interest in controlled corporation; interest held jointly with another person	223,483,650	28.97%
Dr. Wang's SPV 1 ⁽³⁾	Beneficial interest; interest held jointly with another person	223,483,650	28.97%
Dr. Wang's SPV 2 ⁽³⁾	Beneficial interest; interest held jointly with another person	223,483,650	28.97%
Willgenpharma Ltd ⁽³⁾	Beneficial interest; interest held jointly with another person	223,483,650	28.97%
Ms. Zhu Shen ⁽⁴⁾	Interest of spouse	223,483,650	28.97%
Ms. Wang ⁽⁵⁾	Beneficial owner; founder of a discretionary trust; interest held jointly with another person	223,483,650	28.97%
Ms. Wang's SPV ⁽⁵⁾	Beneficial owner; interest held jointly with another person	223,483,650	28.97%
Gloryviewpharma Ltd ⁽⁵⁾	Beneficial interest; interest held jointly with another person	223,483,650	28.97%
Blesspharma Ltd ⁽⁶⁾	Beneficial interest; interest held jointly with another person	223,483,650	28.97%
Mr. Ze Liu ⁽⁷⁾	Interest of spouse	223,483,650	28.97%
Ms. Hu ⁽⁸⁾	Beneficial owner; founder of a discretionary trust; interest held jointly with another person	223,483,650	28.97%
Ms. Hu's SPV ⁽⁸⁾	Beneficial owner; interest held jointly with another person	223,483,650	28.97%
Honourpharma Ltd ⁽⁹⁾	Beneficial interest; interest held jointly with another person	223,483,650	28.97%
BioEngine Capital Holding Limited ⁽¹⁰⁾	Beneficial interest	87,557,000	11.35%
BioEngine Capital Inc. ⁽¹⁰⁾	Interest in controlled corporation	87,557,000	11.35%
Center Laboratories, Inc. ⁽¹⁰⁾	Interest in controlled corporation	87,557,000	11.35%
LAV Coda Limited ⁽¹¹⁾	Beneficial interest	43,134,075	5.46%
LAV Biosciences Fund IV, L.P. ⁽¹¹⁾	Interest in controlled corporation	43,134,075	5.46%
LAV GP IV, L.P. ⁽¹¹⁾	Interest in controlled corporation	43,134,075	5.46%
LAV Corporate IV GP, Ltd. ⁽¹¹⁾	Interest in controlled corporation	43,134,075	5.46%
Mr. Yi Shi ⁽¹¹⁾	Interest in controlled corporation	51,282,225	6.65%
Qiming Venture Partners VI, L.P. ⁽¹²⁾	Beneficial interest	48,305,740	6.26%
Qiming Corporate GP V, Ltd ⁽¹²⁾	Interest in controlled corporation	32,222,000	4.18%
Qiming Corporate GP VI, Ltd ⁽¹²⁾	Interest in controlled corporation	49,605,555	6.43%
HH SPR-III Holdings Limited ⁽¹³⁾	Beneficial interest	56,861,110	7.37%
Hillhouse Capital Management Ltd. ⁽¹³⁾	Interest in controlled corporation	56,861,110	7.37%

Supplementary Information

Notes:

1. All interests stated are long positions.
2. The calculation is based on the total number of 771,462,180 Shares in issue as at June 30, 2022.
3. The entire share capital of each of Dr. Wang's SPV 1 and Dr. Wang's SPV 2 is directly owned by Dr. Wang and indirectly wholly owned by Dr. Wang and Ms. Zhu Shen, the spouse of Dr. Wang, respectively, and the voting rights of the Shares held by Willgenpharma Ltd which are intended to be used for employee incentive purposes are exercisable by Dr. Wang. Accordingly, Dr. Wang is deemed to be interested in such number of Shares held by Dr. Wang's SPV 1, Dr. Wang's SPV 2 and Willgenpharma Ltd. Dr. Wang is also deemed to be interested in all Shares held by Wordspharma Ltd, a company wholly-owned by Ms. Zhu Shen as Ms. Zhu Shen is the spouse of Dr. Wang. In addition, each of Dr. Wang, Dr. Wang's SPV 1, Dr. Wang's SPV 2 and Willgenpharma Ltd is also deemed to be interested in all Shares held by Ms. Wang, Ms. Wang's SPV, Gloryviewpharma Ltd, Blesspharma Ltd, Honourpharma Ltd, Ms. Hu and Ms. Hu's SPV as they are parties acting in concert.
4. The entire share capital of Wordspharma Ltd is wholly owned by Ms. Zhu Shen. Accordingly, Ms. Zhu Shen is deemed to be interested in such number of Shares held by Wordspharma Ltd. In addition, Ms. Zhu Shen is the spouse of Dr. Wang. Accordingly, Ms. Shen Zhu is also deemed to be interested in the Shares in which Dr. Wang is interested.
5. The share capital of Ms. Wang's SPV is indirectly owned by the XM Family Trust as to 99.5% and directly owned by Ms. Wang as to 0.5%. Ms. Wang is the settlor, the protector and the beneficiary of the XM Family Trust and therefore she is deemed to be interested in the shares held by Ms. Wang's SPV under the SFO. The voting rights of the Shares held by Gloryviewpharma Ltd which are intended to use for employee incentive purposes are exercisable by Ms. Wang. Accordingly, Ms. Wang is deemed to be interested in the Shares held by Gloryviewpharma Ltd. In addition, each of Ms. Wang, Ms. Wang's SPV and Gloryviewpharma Ltd are deemed to be interested in all Shares held by Dr. Wang, Dr. Wang's SPV 1, Dr. Wang's SPV 2, Willgenpharma Ltd, Honourpharma Ltd, Blesspharma Ltd, Ms. Hu and Ms. Hu's SPV as they are parties acting in concert.
6. The entire share capital of Blesspharma Ltd is wholly owned by Blesspharma Trust. Ms. Wang and Ms. Hu are the administrators of Blesspharma Trust and are able to exercise the voting rights of the Shares held by Blesspharma Ltd, therefore they are deemed to be interested in the Shares held by Blesspharma Ltd under the SFO. In addition, Blesspharma Ltd is deemed to be interested in all Shares held by Dr. Wang, Dr. Wang's SPV 1, Dr. Wang's SPV 2, Willgenpharma Ltd, Honourpharma Ltd, Ms. Wang, Ms. Wang's SPV, Gloryviewpharma Ltd, Ms. Hu and Hmed Ltd as they are parties acting in concert.
7. Mr. Ze Liu is the spouse of Ms. Wang. Accordingly, Mr. Ze Liu is deemed to be interested in the Shares in which Ms. Wang is interested.
8. The share capital of Ms. Hu's SPV is indirectly owned by the YN Family Trust as to 99.5% and directly owned by Ms. Hu as to 0.5%. Ms. Hu is the settlor, the protector and the beneficiary of the YN Family Trust and therefore she is deemed to be interested in the shares held by Ms. Hu's SPV under the SFO. In addition, each of Ms. Hu and Ms. Hu's SPV is deemed to be interested in all Shares held by Dr. Wang, Dr. Wang's SPV 1, Dr. Wang's SPV 2, Willgenpharma Ltd, Honourpharma Ltd, Ms. Wang, Ms. Wang's SPV, Gloryviewpharma Ltd and Blesspharma Ltd as they are parties acting in concert.
9. The entire share capital of Honourpharma Ltd is directly owned by Dr. Wang. As the actual grantor under the 2021 Stock Incentive Plan, the voting rights of the Shares held by Honourpharma Ltd are held by Ms. Wang and Ms. Hu. Accordingly, Ms. Wang and Ms. Hu are deemed to be interested in such number of Shares held by Honourpharma Ltd under the SFO. In addition, Honourpharma Ltd is deemed to be interested in all Shares held by Dr. Wang, Dr. Wang's SPV 1, Dr. Wang's SPV 2, Willgenpharma Ltd, Blesspharma Ltd, Ms. Wang, Ms. Wang's SPV, Gloryviewpharma Ltd, Ms. Hu and Ms. Hu's SPV as they are parties acting in concert.
10. To the best of our Director's knowledge, BioEngine Capital Holding Limited is a directly wholly owned subsidiary of BioEngine Capital Inc. and an indirectly non-wholly owned subsidiary of Center Laboratories, Inc. Accordingly, BioEngine Capital Inc. and Center Laboratories, Inc. are deemed to be interested in the Shares in which BioEngine Capital Holding Limited is interested. In addition, since Center Laboratories, Inc. is interested in 33.23% of the interests in Fangyuan, Center Laboratories, Inc. is also deemed to be interested in the Shares held by Fangyuan Growth SPC – PCJ Healthcare Fund SP.

Supplementary Information

11. To the best of our Director's knowledge, LAV Coda Limited is wholly owned by LAV Biosciences Fund IV, L.P., a Cayman exempted limited partnership fund. The general partner of LAV Biosciences Fund IV, L.P. is LAV GP IV, L.P., whose general partner is LAV Corporate IV GP, Ltd., a Cayman company owned by Mr. Yi Shi. Therefore, under the SFO, each of LAV Biosciences Fund IV, L.P., LAV GP IV, L.P., LAV Corporate IV GP, Ltd. and Mr. Yi Shi is deemed to be interested in the Shares held by LAV Coda Limited.

To the best of our Director's knowledge, the general partner of LAV Biosciences Fund V, L.P. is LAV GP V, L.P., whose general partner is LAV Corporate V GP, Ltd., a Cayman company owned by Mr. Yi Shi as well. Therefore, under the SFO, each of LAV Biosciences Fund V, L.P., LAV GP V, L.P., LAV Corporate V GP, Ltd. and Mr. Yi Shi is deemed to be interested in the Shares held by LAV Biosciences Fund V, L.P.

Therefore, Mr. Yi Shi is deemed to be interested in the Shares held by both LAV Coda Limited and LAV Biosciences Fund V, L.P.

12. To the best of our Director's knowledge, Qiming Corporate GP V, Ltd is the general partner of Qiming Managing Directors Fund V, L.P. and the ultimate general partner of Qiming Venture Partners V, L.P. Qiming Corporate GP VI, Ltd is the general partner of Qiming Managing Directors Fund VI, L.P. and the ultimate general partner of Qiming Venture Partners VI, L.P. Accordingly, Qiming Corporate GP V, Ltd is deemed to be interested in the Shares held by Qiming Managing Directors Fund V, L.P. and Qiming Venture Partners V, L.P., whereas Qiming Corporate GP VI, Ltd is deemed to be interested in the Shares held by Qiming Managing Directors Fund VI, L.P. and Qiming Venture Partners VI, L.P.

Separately, the voting and investment power of the Shares owned by Qiming Managing Directors Fund V, L.P., Qiming Venture Partners V, L.P., Qiming Managing Directors Fund VI, L.P. and Qiming Venture Partners VI, L.P. are exercised by Mr. Duane Kuang, Mr. Gary Rieschel and Ms. Nisa Bernice Leung, each of whom owns 33.33% of Qiming Corporate GP V, Ltd and Qiming Corporate GP VI, Ltd respectively. Accordingly, each of Mr. Duane Kuang, Mr. Gary Rieschel and Ms. Nisa Bernice Leung is deemed to be interested in the Shares in which Qiming Managing Directors Fund V, L.P., Qiming Venture Partners V, L.P., Qiming Managing Directors Fund VI, L.P. and Qiming Venture Partners VI, L.P. are interested.

13. To the best of our Director's knowledge, Hillhouse Capital Management, Ltd. acts as the sole management company of Hillhouse Fund IV, L.P., which owns HH SPR-III Holdings Limited. Therefore, Hillhouse Capital Management, Ltd. is deemed to be interested in the Shares held by HH SPR-III Holdings Limited.

Save as disclosed above, as at June 30, 2022, our Company had not been notified of any persons (other than a Director or chief executive of our Company) who had an interest or short position in the Shares or underlying Shares that were recorded in the register required to be kept under section 336 of the SFO.

SHARE OPTION SCHEME

For the six months ended June 30, 2022, our Company did not have any share option scheme which was required to be disclosed.

SHARE AWARD SCHEME

On August 31, 2021, our Company has adopted the 2021 Stock Incentive Plan. For details, please refer to the announcements published on websites of the Stock Exchange and our Company dated August 31, 2021 and October 8, 2021.

Supplementary Information

USE OF PROCEEDS FROM GLOBAL OFFERING

Use of Proceeds during the Reporting Period

Our Company's Shares were listed on the Main Board of the Stock Exchange on the Listing Date. Our Group received net proceeds (after deduction of underwriting commissions and related costs and expenses) from its Global Offering of approximately HK\$1,421.8 million, equivalent to RMB1,183.1 million including shares issued as a result of the partial exercise of the over-allotment option (the "Net Proceeds").

As at June 30, 2022, approximately RMB228.4 million of the Net Proceeds had been utilized as follows:

	Allocation of net proceeds from the Global Offering as disclosed in the Prospectus RMB million	Utilized as at December 31, 2021 RMB million	Unutilized as at December 31, 2021 RMB million	Utilized as at June 30, 2022 RMB million	Unutilized as at June 30, 2022 RMB million
Fund registrational clinical trials and preparation for registration filings of JAB-3068 in the Territory	520.6	–	520.6	–	520.6
Fund registrational clinical trials and preparation for registration filings of JAB-3312 in the Territory	213.0	–	213.0	–	213.0
Fund the set-up of our sales and marketing team and commercialization activities of JAB-3068 and JAB-3312 in the Territory	47.3	–	47.3	–	47.3
Fund ongoing and planned clinical trials of JAB-8263	118.3	31.5	86.8	37.5	80.8
Fund ongoing pre-clinical and clinical development of JAB-21822 and the preparation of its IND filing	94.6	93.8	0.8	94.6	–
For the ongoing and planned early-stage drug discovery and development, including pre-clinical and clinical development of our other pipeline assets, discovery and development of new drug candidates	47.3	47.3	–	47.3	–
Fund the planned construction of our in-house GMP-compliant manufacturing facility	94.6	0.6	94.0	1.6	93.0
For working capital and general corporate purposes	47.4	47.4	–	47.4	–
Total	1,183.1	220.6	962.5	228.4	954.7

Supplementary Information

Change in Use of Proceeds from the Global Offering

As at the date of August 23, 2022, our Company has not yet utilized the Net Proceeds of approximately RMB953.3 million (the “**Unutilized Net Proceeds**”). The Board, having considered the reasons set out in “Reasons for the Change in Use of Proceeds” below, resolved to change in use of the Unutilized Net Proceeds. The change and the revised allocation of the Net Proceeds and Unutilized Net Proceeds are set out in the table below.

	Original use of Net Proceeds as disclosed in the Prospectus <i>RMB million</i>	Original percentage of Net Proceeds as disclosed in the Prospectus	Amounts of Unutilized Net Proceeds as at the date of August 23, 2022 <i>RMB million</i>	Changed Use of Proceeds	Revised allocation of Net Proceeds <i>RMB million</i>	Percentage of Net Proceeds (after the proposed change)	Revised amounts of Unutilized Net Proceeds as at the date of August 23, 2022 <i>RMB million</i>
Fund registrational clinical trials and preparation for registration filings of JAB-3068 in the Territory	520.6	44%	520.6	Same as original	300.6	25%	300.6
Fund registrational clinical trials and preparation for registration filings of JAB-3312 in the Territory	213.0	18%	213.0	Fund the clinical trials of JAB-3312 in combination with JAB-21822 and registrational clinical trials and preparation for registration filings of JAB-3312 in the Territory	213.0	18%	213.0
Fund the set-up of our sales and marketing team and commercialization activities of JAB-3068 and JAB-3312 in the Territory	47.3	4%	47.3	Fund the set-up of our sales and marketing team and commercialization activities of 1) JAB-3068 and JAB-3312 in the Territory and 2) JAB-21822 in China	47.3	4%	47.3
Fund ongoing and planned clinical trials of JAB-8263	118.3	10%	79.4	Same as original	118.3	10%	79.4
Fund ongoing pre-clinical and clinical development of JAB-21822 and the preparation of its IND filing	94.6	8%	–	Fund clinical development of JAB-21822, including registrational clinical trials and preparation for NDA	254.6	22%	160.0
For the ongoing and planned early-stage drug discovery and development, including pre-clinical and clinical development of our other pipeline assets, discovery and development of new drug candidates	47.3	4%	–	Same as original	107.3	9%	60.0
Fund the planned construction of our in-house GMP-compliant manufacturing facility	94.6	8%	93.0	Fund the planned decoration of our R&D center and construction of our in-house GMP-compliant manufacturing facility	94.6	8%	93.0
For working capital and general corporate purposes	47.4	4%	–	Same as original	47.4	4%	–
Total	1,183.1	100%	953.3		1,183.1	100%	953.3

Supplementary Information

Reasons for the Change in Use of Proceeds

The reasons for the above changes in the proposed applications of the Net Proceeds and re-allocation of the unutilized amount of the Net Proceeds are as follows:

- (a) The Prospectus stipulates that approximately RMB520.6 million of the Net Proceeds is originally intended to be used for funding registrational clinical trials and preparation for registration filings of JAB-3068 in the Territory. Pursuant to the collaboration agreement with AbbVie, we will perform pre-clinical and early global clinical development activities on SHP2 Products and manufacture (or have manufactured) SHP2 Products for use in clinical studies, in accordance with a development plan and budget. AbbVie would reimburse our costs and expenses incurred from and after July 31, 2022 which do not exceed 105% of the then-current development budget, and we would bear any costs and expenses in excess of the 105% threshold, subject to certain exceptions. As of the date of this interim report, Phase I/IIa monotherapy studies for JAB-3068 have identified the MTD and RP2D and is closed to enrollment in ESCC, HNSCC and NSCLC while the Phase I study for JAB-3068 in combination with anti-PD-1 antibody (JS-001) is expected to be completed by the end of this year. Based on the current progress of JAB-3068 and the advanced development of JAB-21822, the Board is of the view that the decrease of the proportion of the Net Proceeds to fund registrational clinical trials and preparation for registration filings of JAB-3068 in the Territory and the increase of the proportion of the Net Proceeds to fund clinical development JAB-21822 and the ongoing and planned early-stage drug discovery and development is beneficial to the whole R&D progress of our Company.
- (b) The proportion of the Net Proceeds to be used in the clinical development of JAB-21822 has been raised from RMB94.6 million to RMB254.6 million, primarily for the purpose of investing in registrational clinical trials and preparation for NDA submission. Please refer to “Management Discussion and Analysis – Business Review” above for the development progress of JAB-21822.
- (c) The proportion of the Net Proceeds to be used for the ongoing and planned early-stage drug discovery and development has been raised from RMB47.3 million to RMB107.3 million, primarily for the purpose of drug discovery and development of JAB-23400, JAB-30300 and our iADC programs. Please refer to “Management Discussion and Analysis – Business Review” above for the development progress of JAB-23400, JAB-30300 and our iADC programs.

The Board has considered that the development direction of our Company is still in line with the disclosures in the Prospectus in spite of the change in use of the unutilized Proceeds as stated above. The Board confirms that there is no material change in the business nature of our Group as set out in the Prospectus, and considers that the change in the use of the net proceeds is fair and reasonable as this would allow the Group to deploy its financial resources more effectively to enhance the R&D capacity and pipeline of the Group, and is therefore in the best interest of our Company and the Shareholders as a whole.

Save as the changes disclosed above, there are no other proposed changes in the use of the Net Proceeds. The Unutilized Net Proceeds will be applied in a manner consistent with the above planned applications and remains subject to change based on our current and future development of market conditions and actual business needs.

EVENT AFTER THE REPORTING PERIOD

Save as disclosed in this interim report, no important events affecting our Company occurred since the Reporting Period and up to the date of this interim report.

On behalf of the Board of Directors
JACOBIO PHARMACEUTICALS GROUP CO., LTD.
Yingxiang WANG
Chairman

Hong Kong, August 23, 2022

Definitions and Glossary

“2021 Stock Incentive Plan”	the 2021 Stock Incentive Plan adopted by the Board on August 31, 2021 in its present form or as amended from time to time
“AbbVie”	AbbVie Ireland Unlimited Company, incorporated on July 19, 2020 in Ireland, which is a wholly-owned subsidiary of AbbVie Inc. (NYSE: ABBV) and an Independent Third Party
“ACC”	adenoid cystic carcinoma
“ADC”	antibody-drug conjugate, an important class of highly potent biopharmaceutical drugs designed as a targeted therapy for the treatment of cancer
“AML”	acute myeloid leukemia, a type of cancer that progresses rapidly and aggressively, and affects the bone marrow and blood
“Articles of Association”	articles of association of the Company
“Audit Committee”	the audit committee of the Board
“Aurora A”	Aurora A kinase, one of the key regulators of mitosis progression
“Beijing Jacobio”	Jacobio Pharmaceuticals Co., Ltd. (北京加科思新藥研發有限公司), a limited liability company incorporated under the laws of PRC on July 17, 2015, being an indirect wholly-owned subsidiary of our Company
“BET”	bromodomain and extra-terminal; BET proteins interact with acetylated lysine residues in histone to regulate gene expression, and promote aberrant expression of many oncogenes such as MYC, CCND1, and BCL2L1
“BID”	“bis in die,” Latin for twice daily
“Board”	The board of Directors
“BRAF”	B-Raf proto-oncogene, a gene that encodes a protein called B-Raf
“CD73”	ecto-5'-nucleotidase, a surface-expressed enzyme that hydrolyzes AMP into adenosine. CD73 is an immunosuppressive molecule that can be therapeutically targeted to restore effector T-cell function
“CDX”	cell line-derived xenograft, a model used for the research and testing of anti-cancer therapies. Human tumor samples are cultured as cell lines and implanted into mouse models to test the efficacy of anti-tumor compounds in vivo
“China” or “PRC”	the People’s Republic of China
“Company” or “our Company”	JACOBIO PHARMACEUTICALS GROUP CO., LTD. (加科思藥業集團有限公司), an exempted company with limited liability incorporated under the laws of the Cayman Islands on June 1, 2018, which was formerly known as JACOBIO (CAY) PHARMACEUTICALS CO., LTD., the shares of which are listed on the Main Board of the Stock Exchange (Stock Code: 1167)

Definitions and Glossary

“Core Product(s)”	has the meaning ascribed thereto in Chapter 18A of the Listing Rules, which for purposes of this interim report, refers to JAB-3068, JAB-3312 and JAB-21822.
“Corporate Governance Code” or “CG Code”	Corporate Governance Code as set out in Appendix 14 to the Listing Rules
“CRC”	colorectal cancer
“CRO(s)”	contract research organization, a company provides support to the pharmaceutical, biotechnology, and medical device industries in the form of research and development services outsourced on a contract basis
“CRPC”	castration-resistant prostate cancer
“Directors”	director(s) of our Company
“Dr. Wang”	Dr. Yinxiang Wang (王印祥), our executive Director, Chief Executive Officer and Chairman of our Board
“Dr. Wang’s SPV 1”	Yakovpharma Ltd, a limited liability company incorporated under the laws of the BVI which is wholly owned by Dr. Wang
“Dr. Wang’s SPV 2”	Johwpharma Ltd, a limited liability company incorporated under the laws of the BVI which is indirectly wholly owned by Dr. Yinxiang Wang and Ms. Zhu Shen, the spouse of Dr. Wang
“EGFR”	epidermal growth factor receptor
“ESCC”	esophageal squamous cell carcinoma, a high-mortality cancer with complex etiology and progression involving both genetic and environmental factors
“ESOP Platforms”	Willgenpharma Ltd, Gloryviewpharma Ltd, Honourpharma Ltd and Blesspharma Ltd
“G12A/C/D/R/S/V/X”, “G13D”	specific variations in the KRAS protein
“Global Offering”	the offer of Shares for subscription as described in the Prospectus
“GMP”	good manufacturing practice
“Group”, “our Group”, “we”, “us” or “our”	our Company and all of its subsidiaries, or any one of them as the context may require or, where the context refers to any time prior to its incorporation, the business which its predecessors or the predecessors of its present subsidiaries, or any one of them as the context may require, were or was engaged in and which were subsequently assumed by it

Definitions and Glossary

“GTPases”	a large family of hydrolase enzymes that bind to the nucleotide guanosine triphosphate (GTP) and hydrolyze it to guanosine diphosphate (GDP)
“Hebecell”	Hebecell Holding Limited, an exempted company incorporated with limited liability under the Laws of the Cayman Islands
“HER2”	human epidermal growth factor receptor 2, also known as receptor tyrosine-protein kinase ERBB-2. HER2 is a member of the human epidermal growth factor receptor (HER/EGFR/ERBB) family
“HNSCC”	head and neck squamous cell carcinoma
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Hong Kong dollars” or “HK dollars” or “HK\$”	Hong Kong dollars and cents respectively, the lawful currency of Hong Kong
“HRAS”	HRas proto-oncogene, a gene providing instructions for making a protein called H-Ras that is involved primarily in regulating cell division
“IND”	investigational new drug or investigational new drug application, also known as clinical trial application in China
“Independent Third Party”	a person or entity who is not a connected person of our Company under the Listing Rules
“KRAS”	Kirsten rat sarcoma 2 viral oncogene homolog, a signal transducer protein, which plays an important role in various cellular signaling events such as in regulation of cell proliferation, differentiation and migration
“KRAS G12X-mutant”	Multiple mutant forms at codon-12 of the KRAS protein
“Jacobio HK”	JACOBIO (HK) PHARMACEUTICALS CO., LIMITED (加科思(香港)藥業有限公司), a limited liability company incorporated under the laws of Hong Kong on July 3, 2018, being a direct wholly-owned subsidiary of our Company
“Jacobio US”	JACOBIO (US) PHARMACEUTICALS, INC., a limited liability company incorporated under the laws of the State of Delaware on December 20, 2018, being an indirect wholly-owned subsidiary of our Company
“Jacomab”	Jacomab Pharmaceuticals Co., Ltd. (北京加科天實新藥研發有限公司), a limited liability company incorporated under the laws of PRC on December 7, 2016, being an indirect wholly-owned subsidiary of our Company
“Listing”	the listing of our Company on the main board of the Stock Exchange on December 21, 2020

Definitions and Glossary

“Listing Date”	December 21, 2020, being the date on which the Offer Shares were listed and dealings in the Offer Shares first commenced on the Stock Exchange
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended, supplemented or otherwise modified from time to time
“LOF”	loss-of-function
“Main Board”	the stock exchange (excluding the option market) operated by the Stock Exchange which is independent from and operated in parallel with the GEM of the Stock Exchange
“MEK”	mitogen-activated protein kinase kinase (also known as MAPKK), a kinase enzyme which phosphorylates MAPK
“MF”	myelofibrosis, one of a collection of progressive blood cancers known as myeloproliferative neoplasms
“Model Code”	Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix 10 to the Listing Rules
“Ms. Hu”	Ms. Yunyan Hu (胡雲雁), our executive Director and President of Research and Development
“Ms. Hu’s SPV”	Hmed Ltd, a limited liability company incorporated under the laws of the BVI of which the total share capital is indirectly wholly owned by YN Family Trust with Ms. Hu being its beneficiary, protector and settlor
“Ms. Wang”	Ms. Xiaojie Wang (王曉潔), our executive Director and President of Administration
“Ms. Wang’s SPV”	Risepharm Ltd, a limited liability company incorporated under the laws of the BVI of which the total share capital is indirectly wholly owned by XM Family Trust with Ms. Wang being its beneficiary, protector and settlor
“MYC”	a family of regulator genes and proto-oncogenes that code for transcription factors
“naïve”	not having received therapy
“NF1”	a gene located on chromosome 17, which produces a protein called neurofibromin that helps regulate cell growth. The mutated NF1 gene causes a loss of neurofibromin, which allows uncontrolled cells grow
“NMC”	a rare type of cancer that forms in the respiratory tract and other places along the middle of the body, from the head to the abdomen

Definitions and Glossary

“NMPA”	the National Medical Product Administration of the PRC (國家藥品監督管理局), successor to the China Food and Drug Administration or CFDA (國家食品藥品監督管理總局)
“NRAS”	neuroblastoma RAS viral oncogene homolog, which provides instructions for making a protein called N-Ras that is involved primarily in regulating cell division
“NSCLC”	non-small cell lung cancer
“P53”	a type of tumor suppressor gene
“PARP7”	a member of the poly ADP ribose polymerase (PARP) enzymes
“PD-1”	programmed cell death protein 1, an immune checkpoint receptor expressed on T cells, B cells and macrophages. The normal function of PD-1 is to turn off the T cell-mediated immune response as part of the process that stops a healthy immune system from attacking other pathogenic cells in the body. When PD-1 on the surface of a T cell attaches to certain proteins on the surface of a normal cell or a cancer cell, the T cell turns off its ability to kill the cell
“PD-(L)1”	PD-1 ligand 1, which is a protein on the surface of a normal cell or a cancer cell that attaches to certain proteins on the surface of the T cell that causes the T cell to turn off its ability to kill the cancer cell
“PDAC”	pancreatic ductal adenocarcinoma cancer
“Phase I”	study in which a drug is introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion, and if possible, to gain an early indication of its effectiveness
“Phase Ib/IIa”	Phase Ib/IIa is the study that tests the safety, side effects, and best dose of a new treatment. It is conducted in target patient population with selected dose levels. Phase Ib/IIa study also investigates how well a certain type of disease responds to a treatment. In the phase IIa part of the study, patients usually receive multiple dose levels and often include the highest dose of treatment that did not cause harmful side effects in the phase Ia part of the study. Positive results will be further confirmed in a Phase IIb or Phase III study
“Phase II”	study in which a drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases, and to determine dosage tolerance and optimal dosage
“Prospectus”	the prospectus of our Company dated December 9, 2020 being issued in connection with the Listing
“PTPs”	protein tyrosine phosphatases, a family of enzymes essential for numerous cellular processes

Definitions and Glossary

“Q61H”	specific variations in the KRAS protein
“QD”	once daily
“RAS”	a low-molecular-weight GDP/GTP-binding guanine triphosphatase, which is a prototypical member of the small-GTPase superfamily
“RB”	retinoblastoma tumor suppressor, also abbreviated as RB1, a master regulator of the cell cycle and is mutated or functionally inactivated in the majority of human cancers
“Register of Members”	the register of members of our Company
“Renminbi” or “RMB”	Renminbi, the lawful currency of the PRC
“Reporting Period”	the six months ended June 30, 2022
“RP2D”	recommended Phase II dose
“SCLC”	small cell lung cancer
“SFO”	Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)
“Share(s)”	ordinary share(s) with a nominal value of US\$0.0001 each in the share capital of our Company
“Shareholder(s)”	holder(s) of the Shares
“SHP2”	Src homology region 2 domain-containing phosphatase-2, a protein tyrosine phosphatase acting as a key regulator in the RAS signaling pathway
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“TID”	“ter in die”, Latin for three times daily
“U.S. dollars”, “US\$” or “USD”	United States dollars, the lawful currency of the United States
“U.S. FDA”	U.S. Food and Drug Administration

Report on Review of Interim Financial Information

To the Board of Directors of JACOBIO PHARMACEUTICALS GROUP CO., LTD.
(incorporated in the Cayman Islands with limited liability)

INTRODUCTION

We have reviewed the interim financial information set out on pages 45 to 72, which comprises the interim condensed consolidated balance sheet of JACOBIO PHARMACEUTICALS GROUP CO., LTD. (the “Company”) and its subsidiaries (together, the “Group”) as at 30 June 2022 and the interim condensed consolidated statement of loss, the interim condensed consolidated statement of comprehensive loss, the interim condensed consolidated statement of changes in shareholders’ equity and the interim condensed consolidated statement of cash flows for the six-month period then ended, and notes, comprising significant accounting policies and other explanatory information. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of a report on interim financial information to be in compliance with the relevant provisions thereof and International Accounting Standard 34 “Interim Financial Reporting”. The directors of the Company are responsible for the preparation and presentation of this interim financial information in accordance with International Accounting Standard 34 “Interim Financial Reporting”. Our responsibility is to express a conclusion on this interim financial information based on our review and to report our conclusion solely to you, as a body, in accordance with our agreed terms of engagement and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

SCOPE OF REVIEW

We conducted our review in accordance with International Standard on Review Engagements 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

CONCLUSION

Based on our review, nothing has come to our attention that causes us to believe that the interim financial information of the Group is not prepared, in all material respects, in accordance with International Accounting Standard 34 “Interim Financial Reporting”.

PricewaterhouseCoopers
Certified Public Accountants

Hong Kong, 23 August 2022

Interim Condensed Consolidated Statement of Loss

	Note	Six months ended 30 June	
		2022 RMB'000 (Unaudited)	2021 RMB'000 (Unaudited)
Revenue	5	54,687	57,689
Cost of revenue	6	(45,854)	(53,133)
Gross profit		8,833	4,556
Research and development expenses	6	(176,589)	(121,660)
Administrative expenses	6	(22,779)	(18,528)
Other income	7	1,779	3,624
Other gains/(losses) – net	8	53,342	(11,930)
Operating loss		(135,414)	(143,938)
Finance income	9	7,715	7,644
Finance expenses	9	(126)	(303)
Finance income – net	9	7,589	7,341
Loss before income tax		(127,825)	(136,597)
Income tax expense	10	–	–
Loss for the period		(127,825)	(136,597)
Loss attributable to:			
Owners of the Company		(127,825)	(136,597)
Non-controlling interests		–	–
		(127,825)	(136,597)
Loss per share attributable to owners of the Company:			
– Basic and diluted (in RMB per share)	11	(0.17)	(0.18)

The above interim condensed consolidated statement of loss should be read in conjunction with the accompanying notes.

Interim Condensed Consolidated Statement of Comprehensive Loss

	Note	Six months ended 30 June	
		2022 RMB'000 (Unaudited)	2021 RMB'000 (Unaudited)
Loss for the period		(127,825)	(136,597)
Other comprehensive loss:			
<i>Items that may be reclassified to profit or loss:</i>			
Exchange differences on translation of foreign operations	18	<u>241</u>	<u>(38)</u>
Other comprehensive loss for the period, net of tax		241	(38)
Total comprehensive loss		<u>(127,584)</u>	<u>(136,635)</u>
Total comprehensive loss attributable to:			
Owners of the Company		<u>(127,584)</u>	<u>(136,635)</u>
Non-controlling interests		<u>–</u>	<u>–</u>
		<u>(127,584)</u>	<u>(136,635)</u>

The above interim condensed consolidated statement of comprehensive loss should be read in conjunction with the accompanying notes.

Interim Condensed Consolidated Balance Sheet

	Note	As at 30 June 2022 RMB'000 (Unaudited)	As at 31 December 2021 RMB'000 (Audited)
ASSETS			
Non-current assets			
Property, plant and equipment	13	34,412	34,066
Right-of-use assets		4,948	7,706
Intangible assets		1,209	1,548
Long-term investments measured at fair value through profit or loss	4.3, 14	24,851	16,228
Other receivables and prepayments		4,030	19,703
Derivative financial instruments	4.3	6,312	2,856
Total non-current assets		75,762	82,107
Current assets			
Contract assets	5	20,286	64,919
Other receivables and prepayments		38,692	32,675
Derivative financial instruments	4.3	–	4,550
Cash and bank balances	15	1,466,575	1,537,583
Total current assets		1,525,553	1,639,727
Total assets		1,601,315	1,721,834
SHAREHOLDERS' EQUITY			
Equity attributable to owners of the Company			
Share capital	17	510	510
Other reserves	18	3,979,461	3,979,220
Share-based compensation reserve	19	126,665	120,177
Accumulated losses		(2,590,644)	(2,462,819)
Non-controlling interests		1,515,992	1,637,088
Total shareholders' equity		1,515,992	1,637,088

Interim Condensed Consolidated Balance Sheet (Continued)

	Note	As at 30 June 2022 RMB'000 (Unaudited)	As at 31 December 2021 RMB'000 (Audited)
LIABILITIES			
Non-current liabilities			
Lease liabilities		536	1,889
Deferred income		1,817	2,024
Total non-current liabilities		2,353	3,913
Current liabilities			
Trade payables	16	57,190	51,047
Other payables and accruals		21,817	24,868
Lease liabilities		3,375	4,918
Derivative financial instruments	4.3	588	–
Total current liabilities		82,970	80,833
Total liabilities		85,323	84,746
Total equity and liabilities		1,601,315	1,721,834

The above interim condensed consolidated balance sheet should be read in conjunction with the accompanying notes.

The condensed consolidated interim financial information on pages 45 to 72 was approved by the board of Directors on 23 August 2022 and were signed on its behalf

Yinxiang Wang

Name of director

Xiaojie Wang

Name of director

Interim Condensed Consolidated Statement of Changes in Shareholders' Equity

	Note	Attributable to owners of the Company				Subtotal RMB'000	Non- controlling interests RMB'000	Total RMB'000
		Share capital RMB'000	Other reserves RMB'000	Share-based compensation reserve RMB'000	Accumulated losses RMB'000			
Balance at 1 January 2022		510	3,979,220	120,177	(2,462,819)	1,637,088	-	1,637,088
Comprehensive loss								
Loss for the period		-	-	-	(127,825)	(127,825)	-	(127,825)
Exchange differences on translation of foreign operations	18	-	241	-	-	241	-	241
Transactions with owners								
Share-based payments	19	-	-	6,488	-	6,488	-	6,488
Balance at 30 June 2022 (Unaudited)		510	3,979,461	126,665	(2,590,644)	1,515,992	-	1,515,992
		Attributable to owners of the Company						
		Share capital RMB'000	Other reserves RMB'000	Share-based compensation reserve RMB'000	Accumulated losses RMB'000	Subtotal RMB'000	Non- controlling interests RMB'000	Total RMB'000
Balance at 1 January 2021		502	3,846,602	100,728	(2,161,632)	1,786,200	-	1,786,200
Comprehensive loss								
Loss for the period		-	-	-	(136,597)	(136,597)	-	(136,597)
Exchange differences on translation of foreign operations	18	-	(38)	-	-	(38)	-	(38)
Transactions with owners								
Exercise of over-allotment option	17, 18	8	132,823	-	-	132,831	-	132,831
Share-based payments	19	-	-	10,829	-	10,829	-	10,829
Balance at 30 June 2021 (Unaudited)		510	3,979,387	111,557	(2,298,229)	1,793,225	-	1,793,225

The above interim condensed consolidated statement of changes in shareholders' equity should be read in conjunction with the accompanying notes.

Interim Condensed Consolidated Statement of Cash Flows

	Note	Six months ended 30 June	
		2022 RMB'000 (Unaudited)	2021 RMB'000 (Unaudited)
Cash flows from operating activities			
Cash used in operations		(120,861)	(119,601)
Interest received		9,035	4,849
Net cash used in operating activities		(111,826)	(114,752)
Cash flows from investing activities			
Purchase of property, plant and equipment		(2,806)	(7,381)
Purchase of intangible assets		–	(589)
Proceeds from disposal of property, plant and equipment		39	10
Purchase of long-term investments measured at fair value through profit or loss	4.3	(5,000)	–
Proceeds from settlement of deposits with original maturities of over 3 months		–	194,905
Interest received on deposits with original maturities of over 3 months		–	549
Payments for restricted bank deposits		–	(169,001)
Withdraw of restricted bank deposits		3,817	162,766
Proceeds from derivative financial instruments		2,247	853
Net cash (used in)/generated from investing activities		(1,703)	182,112
Cash flows from financing activities			
Principal elements of lease payments		(2,896)	(1,189)
Interest paid		(126)	(108)
Proceeds from exercise of over-allotment option, net of listing expenses	17	–	132,831
Payments for listing expenses		–	(11,892)
Net cash (used in)/generated from financing activities		(3,022)	119,642
Net (decrease)/increase in cash and cash equivalents		(116,551)	187,002
Cash and cash equivalents at beginning of the period		1,527,204	1,430,416
Effects of exchange rate changes on cash and cash equivalents		49,237	(12,267)
Cash and cash equivalents at end of the period	15	1,459,890	1,605,151

The above interim condensed consolidated statement of cash flows should be read in conjunction with the accompanying notes.

Notes to the Condensed Consolidated Interim Financial Information

1 GENERAL INFORMATION

JACOBIO PHARMACEUTICALS GROUP CO., LTD. (the “Company”) was incorporated in the Cayman Islands on 1 June 2018 as an exempted company with limited liability under the Companies Law (Cap.22, Law 3 of 1961 as consolidated and revised) of the Cayman Islands. The address of the Company’s registered office is Walkers Corporate Limited, 190 Elgin Avenue, George Town, Grand Cayman KY1-9008, Cayman Islands.

The Company is an investment holding company. The Company and its subsidiaries (collectively, “the Group”) are principally engaged in research and development of new drugs.

The ordinary shares of the Company were listed on the Main Board of the Stock Exchange of Hong Kong Limited on 21 December 2020.

The condensed consolidated interim financial information is presented in Renminbi (“RMB”) and rounded to nearest thousand yuan, unless otherwise stated.

The condensed consolidated interim financial information was approved for issue by the board of Directors on 23 August 2022.

2 BASIS OF PREPARATION

This condensed consolidated interim financial information has been prepared in accordance with International Accounting Standard 34 “Interim Financial Reporting”. The interim financial information does not include all the notes of the type normally included in an annual financial report. Accordingly, this interim financial information should be read in conjunction with the financial statements for the year ended 31 December 2021 which have been prepared in accordance with International Financial Reporting Standards (“IFRS”) issued by the International Accounting Standards Board (“IASB”), and any public announcements made by the Company during the interim reporting period.

The accounting policies adopted are consistent with those of the annual financial statements for the year ended 31 December 2021, as described in those annual financial statements, except for the adoption of new and amended standards as set out below.

(a) New and amended standards adopted by the Group

The Group has applied the following standards and amendments for the first time for their annual reporting period commencing 1 January 2022:

- Amendments to IAS 16 – Property, plant and equipment – proceeds before intended use
- Amendments to IAS 37 – Onerous contracts – cost of fulfilling a contract
- Amendments to IFRS 3 – Reference to the conceptual framework
- Annual improvements to IFRS standards 2018 – 2020

The amendments listed above did not have any significant impact on the amounts recognised in prior periods and are not expected to significantly affect the current or future periods.

Notes to the Condensed Consolidated Interim Financial Information (Continued)

2 BASIS OF PREPARATION (Continued)

(b) New standards and interpretations not yet adopted

Standards, amendments and interpretations that have been issued but not yet effective and not been early adopted by the Group, are as follows:

		Effective for accounting periods beginning on or after
Amendments to IAS 1	Classification of liabilities as current or non-current	1 January 2023
IFRS 17	Insurance contracts	1 January 2023
Amendments to IAS 1 and IFRS Practice Statement 2	Disclosure of Accounting Policies	1 January 2023
Amendments to IAS 8	Definition of Accounting Estimates	1 January 2023
Amendments to IAS 12	Deferred Tax related to Assets and Liabilities arising from a Single Transaction	1 January 2023
Amendments to IFRS 10 and IAS 28	Sale or contribution of assets between an investor and its associate or joint venture	To be determined

The Group has already commenced an assessment of the impact of these new or revised standards, and amendments, certain of which are relevant to the Group's operations. According to the preliminary assessment made by the directors, no significant impact on the financial performance and positions of the Group is expected when they become effective.

3 ESTIMATES

The preparation of condensed consolidated interim financial information requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

In preparing this condensed consolidated interim financial information, the significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty should be read in conjunction with the Group's annual financial statements for the year ended 31 December 2021.

Notes to the Condensed Consolidated Interim Financial Information (Continued)

4 FINANCIAL RISK MANAGEMENT AND FINANCIAL INSTRUMENTS

4.1 Financial risk factors

The Group's activities expose it to a variety of financial risks: market risk (including foreign exchange risk and fair value interest rate risk), credit risk and liquidity risk.

The condensed consolidated interim financial information does not include all financial risk management information and disclosures should be read in conjunction with the Group's annual financial statements for the year ended 31 December 2021.

There have been no changes in the risk management policies for the period ended 30 June 2022.

4.2 Liquidity risk

The Group aims to maintain sufficient cash to meet operating capital requirements.

The table below analyses the Group's financial liabilities into relevant maturity groupings based on the remaining period at the balance sheet date to the contractual maturity date. The amounts disclosed in the table are the contractual undiscounted cash flows.

	Less than 1 year <i>RMB'000</i>	Between 1 and 2 years <i>RMB'000</i>	Between 2 and 5 years <i>RMB'000</i>	Over 5 years <i>RMB'000</i>	Total <i>RMB'000</i>
As at 30 June 2022 (Unaudited)					
Trade payables	57,190	–	–	–	57,190
Other payables and accruals (excluding non-financial liabilities)	6,517	–	–	–	6,517
Lease liabilities	3,524	545	–	–	4,069
Total	67,231	545	–	–	67,776
As at 31 December 2021 (Audited)					
Trade payables	51,047	–	–	–	51,047
Other payables and accruals (excluding non-financial liabilities)	5,741	–	–	–	5,741
Lease liabilities	5,136	1,932	–	–	7,068
Total	61,924	1,932	–	–	63,856

Notes to the Condensed Consolidated Interim Financial Information (Continued)

4 FINANCIAL RISK MANAGEMENT AND FINANCIAL INSTRUMENTS (Continued)

4.3 Fair value estimation

(a) Fair value hierarchy

This section explains the judgements and estimates made in determining the fair values of the financial instruments that are recognised and measured at fair value in the financial statements. To provide an indication about the reliability of the inputs used in determining fair value, the Group has classified its financial instruments into the three levels prescribed under the accounting standards.

Level 1: The fair value of financial instruments traded in active markets is based on quoted market prices at the end of the reporting period. The quoted market price used for financial assets held by the Group is the current bid price. These instruments are included in level 1.

Level 2: The fair value of financial instruments that are not traded in an active market is determined using valuation techniques which maximise the use of observable market data and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2.

Level 3: If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3.

Notes to the Condensed Consolidated Interim Financial Information (Continued)

4 FINANCIAL RISK MANAGEMENT AND FINANCIAL INSTRUMENTS (Continued)

4.3 Fair value estimation (Continued)

(a) Fair value hierarchy (Continued)

The following table presents the Group's assets and liabilities that were measured at fair value at 30 June 2022 and 31 December 2021:

	As at 30 June 2022 (Unaudited)			
	Level 1 RMB'000	Level 2 RMB'000	Level 3 RMB'000	Total RMB'000
Assets				
Long-term investments measured at fair value through profit or loss	–	–	24,851	24,851
Derivative financial instruments	–	–	6,312	6,312
	–	–	31,163	31,163
Liabilities				
Derivative financial instruments	–	588	–	588
	As at 31 December 2021 (Audited)			
	Level 1 RMB'000	Level 2 RMB'000	Level 3 RMB'000	Total RMB'000
Assets				
Long-term investments measured at fair value through profit or loss	–	–	16,228	16,228
Derivative financial instruments	–	4,550	2,856	7,406
	–	4,550	19,084	23,634

Notes to the Condensed Consolidated Interim Financial Information (Continued)

4 FINANCIAL RISK MANAGEMENT AND FINANCIAL INSTRUMENTS (Continued)

4.3 Fair value estimation (Continued)

(b) Valuation techniques used to determine fair values

Specific valuation techniques used to value financial instruments include:

- Quoted market prices or dealer quotes for similar instruments;
- Back-solve method and equity allocation model based on a combination of observable and unobservable inputs; and
- Black-Scholes option pricing model and the forward pricing model based on a combination of observable and unobservable inputs.

(c) Fair value measurements using significant unobservable inputs (level 3)

The following table presents the changes in level 3 items for the six months ended 30 June 2022 and 2021:

	Long-term investments measured at fair value through profit or loss <i>RMB'000</i>	Derivative financial instruments <i>RMB'000</i>	Total <i>RMB'000</i>
As at 1 January 2021 and 30 June 2021 (Unaudited)	–	–	–
As at 1 January 2022	16,228	2,856	19,084
Additions	5,000	–	5,000
Amounts recognised in profit or loss	–	–	–
Gains on fair value changes	3,623	3,456	7,079
As at 30 June 2022 (Unaudited)	24,851	6,312	31,163
Net unrealised gains for the period	3,623	3,456	7,079

There were no transfers between levels 1, 2 and 3 for recurring fair value measurements during the six months ended June 30, 2022 and 2021.

Notes to the Condensed Consolidated Interim Financial Information (Continued)

4 FINANCIAL RISK MANAGEMENT AND FINANCIAL INSTRUMENTS (Continued)

4.3 Fair value estimation (Continued)

(d) Valuation processes

The Group has a team that manages the valuation of level 3 instruments for financial reporting purposes. The team manages the valuation exercise of the investments on a case by case basis. At least once every year, the team would use valuation techniques to determine the fair value of the Group's level 3 instruments. External valuation experts will be involved when necessary.

(e) Valuation inputs and relationships to fair value

The following table summarises the quantitative information about the significant unobservable inputs used in level 3 fair value measurements:

Description	Fair value at		Unobservable inputs	Range of inputs		Relationship of unobservable inputs to fair value
	30 June 2022	31 December 2021		30 June 2022	31 December 2021	
	RMB'000 (Unaudited)	RMB'000 (Audited)				
Long-term investments measured at fair value through profit or loss	24,851	16,228	Expected volatility	52.03%-77.82%	56.47%-81.12%	The higher the expected volatility, the lower the fair value
			Discount for lack of marketability ("DLOM")	24.22%-30.10%	26.28%-30.90%	The higher the DLOM, the lower the fair value
			Risk-free rate	2.88%-3.02%	1.31%	The higher the risk-free rate, the lower the fair value
Derivative financial instruments	6,312	2,856	Risk-free rate	1.88%-2.83%	0.24%-0.60%	The higher the risk-free rate, the higher the fair value

The carrying amounts of the Group's other financial assets and liabilities, including cash and bank balances, other receivables, lease liabilities, trade payables and other payables, approximate their fair values.

Notes to the Condensed Consolidated Interim Financial Information (Continued)

5 SEGMENT AND REVENUE INFORMATION

Management has determined the operating segments based on the reports reviewed by the chief operating decision-maker (the “CODM”). The CODM, who is responsible for allocating resources and assessing performance of the operating segment, has been identified as the executive directors of the Group.

(a) Description of segments

The Group is principally engaged in the research and development of new drugs. The CODM reviews the operating results of the business as one operating segment to make decisions about resources to be allocated. Therefore, the CODM regards that there is only one segment which is used to make strategic decisions.

(b) License and collaboration agreement with a customer

The Group recognised revenue totalled RMB54,687,000 for the six months ended 30 June 2022 (six months ended 30 June 2021: RMB57,689,000) in relation to a license and collaboration agreement entered by the Group with a customer (the “Agreement”). Under the terms of the Agreement, the Group agreed to grant licenses of certain intellectual properties and to provide research and development services in relation to certain licensed products to this customer. The considerations of the Agreement consist of non-refundable upfront payment, reimbursements for research and development costs incurred, and variable considerations including milestone payments and royalties on net sales of the licensed products.

(c) An analysis of revenue from contracts with customers is as follows:

	Six months ended 30 June	
	2022	2021
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Revenue from the Agreement	<u>54,687</u>	<u>57,689</u>

The Group derives revenue from the transfer of goods and services over time and at a point in time as follows:

	Six months ended 30 June	
	2022	2021
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Timing of revenue recognition:		
Over time	<u>54,687</u>	<u>57,689</u>

Notes to the Condensed Consolidated Interim Financial Information (Continued)

5 SEGMENT AND REVENUE INFORMATION (Continued)

(d) Assets related to contracts with customers

The Group has recognised the following assets related to contracts with customers:

	As at 30 June 2022 <i>RMB'000</i> (Unaudited)	As at 31 December 2021 <i>RMB'000</i> (Audited)
Contract assets relating to the Agreement	20,286	64,919
Less: loss allowance	–	–
Current portion	<u>20,286</u>	<u>64,919</u>

6 EXPENSES BY NATURE

	Six months ended 30 June	
	2022 <i>RMB'000</i> (Unaudited)	2021 <i>RMB'000</i> (Unaudited)
Testing fee	97,608	91,448
Employee benefits expenses	78,370	59,274
Raw materials and consumables used	41,662	21,057
Professional services expenses	8,747	4,728
Depreciation and amortisation	6,408	4,885
Utilities and office expenses	3,830	4,162
Short-term leases expenses	3,618	3,658
Auditor's remuneration	1,008	990
Others	3,971	3,119
Total	<u>245,222</u>	<u>193,321</u>

Notes to the Condensed Consolidated Interim Financial Information (Continued)

7 OTHER INCOME

	Six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 RMB'000 (Unaudited)
Other income from a related party (Note 21 (c))	1,284	–
Government grants	495	3,624
	<u>1,779</u>	<u>3,624</u>

8 OTHER GAINS/(LOSSES) – NET

	Six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 RMB'000 (Unaudited)
Net foreign exchange gains/(losses)	49,154	(14,631)
Fair value changes on long-term investments measured at fair value through profit or loss	3,623	–
Net fair value gains on derivative financial instruments	565	2,701
	<u>53,342</u>	<u>(11,930)</u>

9 FINANCE INCOME – NET

	Six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 RMB'000 (Unaudited)
Finance income		
– Interest income	<u>7,715</u>	<u>7,644</u>
Finance expenses		
– Interest expenses on lease liabilities	<u>(126)</u>	<u>(303)</u>
Finance income – net	<u>7,589</u>	<u>7,341</u>

Notes to the Condensed Consolidated Interim Financial Information (Continued)

10 INCOME TAX EXPENSE

	Six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 RMB'000 (Unaudited)
Current income tax expense	–	–
Deferred income tax expense	–	–
	–	–
	–	–

(a) The Group's principal applicable taxes and tax rates are as follows:

Cayman Islands

Under the prevailing laws of the Cayman Islands, the Company is not subject to tax on income or capital gains. In addition, no Cayman Islands withholding tax is payable on dividend payments by the Company to its shareholders.

Hong Kong

Hong Kong profits tax rate is 8.25% for assessable profits on the first HKD2 million and 16.5% for any assessable profits in excess. No Hong Kong profit tax was provided for as there was no estimated assessable profit that was subject to Hong Kong profits tax during the six months ended 30 June 2022 and 2021.

United States

The subsidiary incorporated in Massachusetts, United States is subject to statutory United States federal corporate income tax at a rate of 21%. It is also subject to the state income tax in Massachusetts at a rate of 8.00% during the six months ended 30 June 2022 and 2021.

Mainland China

Pursuant to the PRC Enterprise Income Tax Law and the respective regulations, the subsidiaries which operate in Mainland China are subject to enterprise income tax at a rate of 25% on the taxable income.

Pursuant to the relevant laws and regulations, a subsidiary of the Company has been eligible as a High/New Technology Enterprise (“HNTE”) which is subject to a tax concession rate of 15% during the six months ended 30 June 2022 and 2021.

According to the relevant laws and regulations promulgated by the State Administration of Taxation of the PRC that has been effective from 2018 onwards, enterprise engaging in research and development activities are entitled to claim 175% of their research and development expenditures incurred as tax deductible expenses when determining their assessable profits for that year.

Notes to the Condensed Consolidated Interim Financial Information (Continued)

11 LOSS PER SHARE

(a) Basic loss per share

Basic and diluted loss per share reflecting the effect of the issuance of ordinary shares by the Company are presented as follows.

Basic loss per share is calculated by dividing the loss attributable to shareholders of the Company by the weighted average number of ordinary shares outstanding.

	Six months ended 30 June	
	2022	2021
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Loss attributable to owners of the Company for the period (RMB'000)	(127,825)	(136,597)
Weighted average number of fully paid ordinary shares in issue (in thousands) (i)	751,442	746,365
Basic loss per share (in RMB per share)	(0.17)	(0.18)

(i) Movement of number of fully paid ordinary shares outstanding for the periods are shown in Note 17.

As at 30 June 2022, 32,690,345 shares (30 June 2021: 32,690,345 shares) are relevant to share-based payments of the Group, 12,832,730 shares (30 June 2021: 8,766,780 shares) of which have been vested and included in the calculation of basic loss per share, and the remaining 19,857,615 (30 June 2021: 23,923,565 shares) shares have not been included in the calculation of loss per share.

(b) Diluted loss per share

The Group had potential dilutive shares throughout the six months ended 30 June 2022 and 2021 related to the shares held for share award scheme. Due to the Group's negative financial results for the six months ended 30 June 2022 and 2021, shares held for share award scheme has anti-dilutive effect on the Group's loss per share. Thus, diluted loss per share is equivalent to the basic loss per share.

Notes to the Condensed Consolidated Interim Financial Information (Continued)

12 DIVIDEND

No dividend has been declared by the Company for the six months ended 30 June 2022 (six months ended 30 June 2021: nil).

13 PROPERTY, PLANT AND EQUIPMENT

	Machinery and equipment <i>RMB'000</i>	Office equipment and furniture <i>RMB'000</i>	Leasehold improvement <i>RMB'000</i>	Total <i>RMB'000</i>
As at 31 December 2021 (Audited)				
Cost	45,443	4,582	10,202	60,227
Accumulated depreciation	(15,301)	(2,824)	(8,036)	(26,161)
Net book value	30,142	1,758	2,166	34,066
Six months ended 30 June 2022				
Opening net book amount	30,142	1,758	2,166	34,066
Additions	1,339	1,378	944	3,661
Disposals	(39)	–	–	(39)
Depreciation charge	(2,267)	(530)	(514)	(3,311)
Effects of exchange rate changes	35	–	–	35
Closing net book value	29,210	2,606	2,596	34,412
As at 30 June 2022 (Unaudited)				
Cost	46,778	5,960	11,146	63,884
Accumulated depreciation	(17,568)	(3,354)	(8,550)	(29,472)
Net book value	29,210	2,606	2,596	34,412

Notes to the Condensed Consolidated Interim Financial Information (Continued)

14 LONG-TERM INVESTMENTS MEASURED AT FAIR VALUE THROUGH PROFIT OR LOSS

	As at 30 June 2022 <i>RMB'000</i> (Unaudited)	As at 31 December 2021 <i>RMB'000</i> (Audited)
--	---	---

Non-current assets

Preferred shares investments (a)	<u>24,851</u>	<u>16,228</u>
----------------------------------	---------------	---------------

- (a) The investees of these preferred shares investments are principally engaged in research and development in biotechnology field.

The Company's preferred shares investment in Hebecell Holding Limited ("Hebecell"), over which the Company has significant influence, was accounted as financial assets measured at fair value through profit or loss. The Company's commitments to further purchase and subscribe for preferred shares of Hebecell at a fixed purchase price were recognised as derivative financial instruments.

15 CASH AND BANK BALANCES

	As at 30 June 2022 <i>RMB'000</i> (Unaudited)	As at 31 December 2021 <i>RMB'000</i> (Audited)
--	---	---

Cash at bank	<u>1,466,575</u>	<u>1,537,583</u>
--------------	------------------	------------------

Reconciliation to interim condensed consolidated statement of cash flows:

	As at 30 June 2022 <i>RMB'000</i> (Unaudited)	As at 31 December 2021 <i>RMB'000</i> (Audited)
--	---	---

Cash and bank balances	1,466,575	1,537,583
Less: Restricted bank deposits (a)	<u>(6,685)</u>	<u>(10,379)</u>

Cash and cash equivalents	<u>1,459,890</u>	<u>1,527,204</u>
---------------------------	------------------	------------------

- (a) Restricted bank deposits are the retention deposits for the Group's foreign currency exchange forward contracts and the retention deposits for a performance guarantee of a lease contract.

Notes to the Condensed Consolidated Interim Financial Information (Continued)

16 TRADE PAYABLES

The aging analysis of trade payables based on the invoice date is as follows:

	As at 30 June 2022 RMB'000 (Unaudited)	As at 31 December 2021 RMB'000 (Audited)
Less than 1 year	57,190	51,047

17 SHARE CAPITAL

	Number of ordinary shares	Nominal value of ordinary shares USD'000	Number of preferred shares	Nominal value of preferred shares USD'000
Authorised:				
As at 31 December 2021, 1 January 2022 and 30 June 2022	1,000,000,000	100	–	–
	Number of shares in equity	Share capital		
		USD'000	RMB'000	
Issued and fully paid:				
As at 1 January 2022 and 30 June 2022 (Unaudited)	771,462,180	76	510	
As at 1 January 2021	759,653,880	75	502	
Exercise of over-allotment option (a)	11,808,300	1	8	
As at 30 June 2021 (Unaudited)	771,462,180	76	510	

- (a) On 13 January 2021, the international underwriters of the global offering partially exercised the over-allotment option, pursuant to which the Company issued 11,808,300 ordinary shares with par value of USD0.0001 each at a price of HKD14.00 per share and USD1,000 (equivalent to approximately RMB8,000) are credited to share capital, and remaining amounts, after netting of listing expenses, RMB132,823,000 are credited to capital reserve.

Notes to the Condensed Consolidated Interim Financial Information (Continued)

18 OTHER RESERVES

	Capital reserve <i>RMB'000</i>	Foreign currency translation reserve (a) <i>RMB'000</i>	Total <i>RMB'000</i>
As at 1 January 2022	3,979,361	(141)	3,979,220
Exchange differences on translation of foreign operations	–	241	241
As at 30 June 2022 (Unaudited)	3,979,361	100	3,979,461
As at 1 January 2021	3,846,538	64	3,846,602
Exercise of over-allotment option (Note 17(a))	132,823	–	132,823
Exchange differences on translation of foreign operations	–	(38)	(38)
As at 30 June 2021 (Unaudited)	3,979,361	26	3,979,387

- (a) Foreign currency translation reserve represents the difference arising from the translation of financial information of the subsidiaries of the Company, which have the functional currency different from the presentation currency of the Company.

Notes to the Condensed Consolidated Interim Financial Information (Continued)

19 SHARE-BASED PAYMENTS

(a) 2017 Plan and Modification of 2017 Plan

On 1 January 2017, 4,540,000 share options of a subsidiary of the Company were granted to employees ("2017 Plan") with the exercise price of RMB1.00 per share option. On 1 March 2020, 2,231,864 restricted shares were granted to the same employees at a consideration of RMB0.1 per ordinary share, taking place of the 4,540,000 share options under 2017 Plan ("Modification of 2017 Plan"). All expenses arising from Modification of 2017 Plan have been recognised in profit and loss before 1 January 2022.

(b) 2020 employee incentive plan

On 1 March 2020, the board of Directors passed a resolution to adopt 2020 employee incentive plan ("2020 Plan"). The restricted shares and share options granted under the 2020 Plan are as follows:

- (i) On 1 March 2020, 608,205 restricted shares were granted to certain employees of the Group at a consideration of RMB0.1 per share. The Group records the expenses arising from 2020 Plan in the consolidated statement of comprehensive loss pursuant to the vesting schedule from March 2020 to March 2025.
- (ii) On 16 July 2020, 1,200,000 share options of Willgenpharma Ltd, an employee incentive platform of the Company, were granted to 2 employees, and each 25% of the share options granted will be vested on the 2nd, 3rd, 4th and 5th year anniversary of the grant date, respectively. The share options vested shall become exercisable commencing from the 5th year anniversary of the grant date. The expiry date of these share options is the 90 days following the 5th year anniversary of the grant date. The exercise price of these options is USD0.0001 per ordinary share and shall be adjusted to USD4.00 per ordinary share retroactively if these entire options are not fully vested.

During the six months ended 30 June 2022, 200,000 share options thereof were forfeited (six months ended 30 June 2021: nil).

- (iii) On 20 July 2020, 50,000 restricted shares were granted to an individual and vested immediately. On the same day, 388,000 restricted shares were granted to the founders of the Company, and each one third of the restricted shares granted will be vested on the 1st, 2nd and 3rd year anniversary of the grant date, respectively. 198,000 restricted shares thereof were at a consideration of USD0.0001 per ordinary share, and the other 240,000 restricted shares granted were at a consideration of RMB0.1 per ordinary share.

Upon the capitalisation issue undertaken in 2020, the number of shares granted under Modification of 2017 Plan (Note 19(a)) and 2020 Plan (Notes 19(b)(i), 19(b)(ii) and 19(b)(iii)) are adjusted to five times of the original correspondingly. The adjustment mentioned above did not result in any incremental fair value granted.

- (iv) On 14 September 2021, 300,000 restricted shares were granted to an individual at a consideration of RMB0.02 per ordinary share. For 250,000 restricted shares thereof, each 25% will be vested on the 1st, 2nd, 3rd and 4th year anniversary of the grant date, respectively. For the remaining 50,000 restricted shares, all shares will be vested on the 5th year anniversary of the grant date.

Notes to the Condensed Consolidated Interim Financial Information (Continued)

19 SHARE-BASED PAYMENTS (Continued)

(b) 2020 employee incentive plan (Continued)

- (v) On 25 March 2022, 250,000 share options of Willgenpharma Ltd were granted to an individual, which can be vested on the 2nd year anniversary of the grant date if a non-market performance condition is met. The expiry date of these share options is 18 October 2025. The fair value of the share options on the grant date was USD0.52 per share by using binomial model. Key inputs are set as below:

Exercise price per ordinary share	USD0.8
The Company's share price on the grant date	HKD7.38
Risk-free rate	2.52%
Expected volatility	68.81%

Save as the forfeited share options mentioned in Note 19(b)(ii), no restricted share or share option under the 2020 Plan was forfeited during the six months ended 30 June 2022 (six months ended 30 June 2021: nil). As at 30 June 2022, 1,125,000 shares have not been granted under the 2020 Plan.

(c) 2021 employee incentive plan

On 31 August 2021, the board of Directors passed a resolution to adopt 2021 employee incentive plan ("2021 Plan"). Pursuant to the 2021 Plan, shares may be granted according to the instructions from certain directors of the Company, and the maximum aggregate number of shares underlying the 2021 Plan is 10,000,000 shares plus shares purchased on the open market from time to time. As at 30 June 2022, no share has been granted under the 2021 Plan.

(d) Expenses arising from share-based payment transactions

	Six months ended 30 June	
	2022	2021
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
2017 Plan and Modification of 2017 Plan	–	371
2020 Plan	6,488	10,458
	6,488	10,829

As at 30 June 2022, the accumulated expenses arising from share-based payment transactions amounting to RMB126,665,000 were recognised in the share-based compensation reserve (30 June 2021: RMB111,557,000).

Notes to the Condensed Consolidated Interim Financial Information (Continued)

20 COMMITMENTS

(a) Capital commitments

The following is the details of capital expenditure contracted for but not provided in the condensed consolidated interim financial information.

	As at 30 June 2022 RMB'000 (Unaudited)	As at 31 December 2021 RMB'000 (Audited)
Contracted but not provided for		
– Property, plant and equipment	4,185	3,782
– Investments (i)	151,006	148,453
	155,191	152,235

(i) The Company entered into a share purchase agreement with Hebecell in August 2021, pursuant to which the Company has agreed to further purchase and subscribe for preferred shares of Hebecell at a fixed purchase price with a total consideration of USD22,500,000, which approximately equivalent to RMB151,006,000 as at 30 June 2022.

(ii) Capital commitments related to the new-drug research and development base (the “Base”)

In September 2019, the Group entered into an agreement with Beijing Economic-Technological Development Area Administration Commission on a total capital expenditure of no less than RMB140 million for the Base. The capital expenditure is expected to be incurred before the end of 2025.

In October 2021, the Group entered into a lease contract with Beijing Yizhuang Shengyuan Investment and Development Group Co., Ltd. (the “Lease Contract”), pursuant to which the Group has agreed to lease the Base for 10 years from commencement date of the lease with an aggregate lease payment of approximately RMB162 million.

Notes to the Condensed Consolidated Interim Financial Information (Continued)

20 COMMITMENTS (Continued)

(b) Operating lease commitments

As at 30 June 2022 and 31 December 2021, the future aggregate minimum lease payment for short-term lease and low-value lease under irrevocable lease contracts are as follows:

	As at 30 June 2022 RMB'000 (Unaudited)	As at 31 December 2021 RMB'000 (Audited)
Less than 1 year	230	3,873

21 RELATED PARTY TRANSACTIONS

Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Parties are also considered to be related if they are subject to common control. Members of key management and their close family member of the Group are also considered as related parties.

(a) Name and relationship with related parties

Name of related party	Nature of relationship
Hebecell	Associate of the Group

The following is a summary of the significant transactions carried out between the Group and its related parties in the ordinary course of business during the six months ended 30 June 2022 and 2021.

Notes to the Condensed Consolidated Interim Financial Information (Continued)

21 RELATED PARTY TRANSACTIONS (Continued)

(b) Key management compensation

Key management includes directors and senior management. The compensation paid or payable to key management for employee services is shown below:

	Six months ended 30 June	
	2022	2021
	<i>RMB'000</i>	<i>RMB'000</i>
	(Unaudited)	(Unaudited)
Salaries and other short-term employee benefits	6,263	7,480
Share-based compensation expenses	5,485	7,082
	11,748	14,562

(c) Transactions with other related parties

The following transactions occurred with related parties:

	Six months ended 30 June	
	2022	2021
	<i>RMB'000</i>	<i>RMB'000</i>
	(Unaudited)	(Unaudited)
Provide consulting services		
Hebecell	1,284	–

Notes to the Condensed Consolidated Interim Financial Information (Continued)**21 RELATED PARTY TRANSACTIONS** (Continued)**(d) Balances with related parties**

	As at 30 June 2022 RMB'000 (Unaudited)	As at 31 December 2021 RMB'000 (Audited)
Other receivables from related parties		
Hebecell	337	708

22 SUBSEQUENT EVENT

The Group does not have any significant subsequent event that need to be disclosed.